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57) ABSTRACT 
The present invention provides various novel matrix-sup 
ported texaphyrins in which a polymeric or solid matrix is 
covalently modified by the addition of one or more texa 
phyrins or texaphyrin derivatives. Described are methods of 
making various polymer-supported texaphyrins, including 
texaphyrin chromatographic supports, and devices such as 
catheters, as may be used, for example, in the separation of 
neutral and anionic species and in applications concerning 
phosphate ester hydrolysis, other catalytic schemes, MRI, 
and PDT. 
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TEXAPHYRN SOLD SUPPORTS AND 
DEVICES 
The U.S. government has certain rights in the present 
invention pursuant to grant AI 28845 from the National 
Institutes of Health. 
The present application is a continuation-in-part appli 
cation of copending U.S. Ser. No. 08/236,218 filed Apr. 28, 
1994. U.S. Ser. No. 08/236,218 is a continuation-in-part 
application of PCT/US93/09994 (W094/09003), filed Oct. 
18, 1993; which is a continuation-in-part application of U.S. 
Ser. No. 07/964,607, filed Oct. 21, 1992 now U.S. Pat. No. 
5,457,195. U.S. Ser. No. 07/964,607 is a continuation-in 
part application of U.S. Ser. No. 07/454.298 filed Dec. 21, 
1989, since issued as U.S. Pat. No. 5,159,065. The entire 
contents of the patent and patent applications are incorpo 
rated by reference herein. 
FIELD OF THE INVENTION 
The present invention relates to the field of macrocyclic 
expanded porphyrins and, more particularly, concerns texa 
phyrins and texaphyrin derivatives that are conjugated to a 
polymer or solid matrix to form a polymer- or matrix 
supported texaphyrin. Disclosed are polymer-supported 
texaphyrins including silica gel, polyacrylamide, and poly 
styrene; matrix-supported texaphyrins including resins, 
plastics and glass; texaphyrin-bearing apparati and devices, 
such as chromatographic supports; and methods of making 
and using these solid-supported texaphyrins, e.g., as in the 
separation or purification of metals, anions and other 
molecular species, and in catalyzing various chemical reac 
tions, such as phosphate ester hydrolysis. 
BACKGROUND OF THE INVENTION 
Expanded porphyrins are large pyrrole-containing mac 
rocyclic analogues of the porphyrins. A number of expanded 
porphyrin systems are now known. Those fully conjugated 
examples that contain more than four pyrrolic subunits 
include the Smaragdyrins, Sapphyrins, pentaphyrins, hexa 
phyrins, and superphthalocyanines. 
A class of expanded porphyrins was developed based on 
the Schiff base condensation between a diformyltripyrrane 
and an aromatic 1,2-diamine'. This class of expanded por 
phyrins, known as the texaphyrins, describes an aromatic 
22It benzannulene containing both 18- and 22-7-electron 
delocalization pathways'. The stabilization gained when the 
texaphyrin macrocycle becomes aromatic allows for con 
siderable chemistry that is not possible in other pyrrole 
based macrocyclic systems. 
The texaphyrins previously described, however, are 
known only to be of the character such that they are 
monomers and aggregated monomers in solution. Thus, 
even though the texaphyrins possess absolutely unique prop 
erties, their uses have previously been limited to homoge 
neous systems, not allowing for the facile separation of the 
texaphyrin following the procedure. This deficiency limited 
the utility of texaphyrins to potential applications where the 
texaphyrin compound could be removed readily following 
the procedure in which it was used. 
The development of a texaphyrin that remains in contact 
with solution but is mechanically separated would, there 
fore, represent a significant advance. Such systems would 
have potential for use in improved applications in photody 
namic therapy (PDT) and magnetic resonance imaging 















separation applications, including those based on high per 
formance liquid chromatography (HPLC). 
Immobilized texaphyrin systems would be especially use 
ful if they could be made to retain the enhanced stability 
found when a texaphyrin is complexed to a lanthanide metal. 
Indeed, there is a significant need in the art for such a system 
as there is currently no means for effecting the stable 
complexation of lanthanides on a solid-support. The devel 
opment of such a system would allow for heterogeneous 
catalysis, where it is important for the substrate to remain 
distinct from the metal complex. 
The potential for subjecting solid-supported texaphyrins 
to harsh conditions, such as elevated temperatures and 
organic solvents, without breakdown of the catalyst would 
also be significantly increased. The development of immo 
bilized texaphyrins could also prove to be useful in other 
areas, such as in the catalysis of certain hydrolytic reactions 
and the concomitant separation or purification of the indi 
vidual products. 
SUMMARY OF THE INVENTION 
The present invention addresses the above and several 
other shortcomings in the prior art through the synthesis of 
various matrix-supported expanded porphyrin compositions 
and devices. In particular aspects, the invention provides 
novel matrix-supported texaphyrins, including texaphyrin 
containing chromatographic supports and devices, including 
catheters. Methods of making such matrix-supported texa 
phyrins are also disclosed, as are methods of using these 
compositions and devices, for example, in the separation and 
purification of anions or neutral molecular species, in the 
hydrolysis of molecules containing phosphate esters, as 
catalysts for hydrogenation and polymerization reactions 
and in photodynamic therapy (PDT) and magnetic resonance 
imaging enhancement (MRI). 
The synthesis of texaphyrin compounds linked to solid 
support systems represents a considerable advantage, not 
only in terms of lanthanide complexation, but also as it 
allows binding of other metals and anions under conditions 
of site isolation. This, in turn, provides an important advan 
tage in applications involving chromatography, such as the 
separation of molecular species or in the hydrolysis of 
compounds and separation of products, in a variety of 
catalytic mechanisms, including racemate resolution, and in 
MRI and PDT. 
The matrix of the matrix-supported texaphyrin may be a 
polymeric- or a solid-support matrix. A polymer of a poly 
mer-support matrix may be polystyrene, polyethylene, poly 
acrylamide, polypropylene, polyamide, Merrifield resin, 
sepharose, agarose, polystyrene, polydivinylbenzene, cellu 
lose, alginic acid, chitosan, chitin, polystyrene-benzhydry 
lamine resin, an acrylic ester polymer, a lactic acid polymer, 
a texaphyrin multimer or a sapphyrin multimer. The solid 
support may be silica, silica gel, amino-functionalized silica 
gel, alumina, clay, Zeolite, glass, controlled pore glass or 
montnorillonite. 
The invention therefore encompasses texaphyrin deriva 
tives, conjugates and polymers thereof, as formulated into 
matrix-supported texaphyrins. In a general and overall 
sense, included within the novel compositions of the inven 
tion are matrix-supported texaphyrins that include one or 
more texaphyrin monomers, texaphyrin derivatives or con 
jugates or polymers thereof, whether or not the matrix 
supported material also contains other groups, such as 
additional functional groups, or even Sapphyrins. 
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As used herein, a texaphyrin is defined as a class of 
expanded porphyrins that is based on the Schiff base con 
densation between a diformytripyrrole and an o-phenylene 
diamine. The synthesis of texaphyrins depends on the 
simple, high yielding synthesis of tripyrroles. Following the 
synthesis of the tripyrrole is an acid-catalyzed condensation 
between a diformyltripyrrole and an o-phenylenediamine 
derivative. This results in the production of tripyrrole 
containing Schiffbase macrocycles referred to as reduced or 
sp texaphyrins. Subsequent 4-electron oxidation either in 
the presence or absence of a metal cation gives rise to the 
final aromatic, or sp', form of the texaphyrin. 
Any texaphyrin, or derivative thereof, may be linked to a 
solid-support in accordance with the present invention. 
Structure I sets forth the general structure for a texaphyrin 
macrocycle. 
Texaphyrins may have a variety of substituents at the 
various R positions, as exemplified by hydrogen, halide, 
hydroxyl, alkyl, alkene, alkyne, aryl, haloalkyl, nitro, 
formyl, acyl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, gly 
col, polyglycol, thiol, thioalkyl, aminoalkyl, alkoxyalkyl, 
aryloxyalkyl, alkyloxycarbonyl, aryloxycarbonyl, aldehyde, 
ether, ketone, carboxylic acid, saccharide, phosphate, phos 
phonate, sulfate, phosphate substituted alkyl, phosphonate 
substituted alkyl, sulfate substituted alkyl, carboxy, carboxy 
alkyl, carboxyamidealkyl, a nucleobase, modified nucleo 
base, oligonucleotide, antibody, hormone, amino acid, pep 
tide, polypeptide, a peptide having affinity for a biological 
receptor, a sugar, sugar derivative, polysaccharide, alkylat 
ing agent, steroid, steroid derivative, one or more sapphy 
rins, rubyrins, texaphyrins or derivatives thereof. However, 
it will be understood that the foregoing list is exemplary and 
is not meant to be exhaustive. M is hydrogen or a metal 
cation. 
Structures II and III show texaphyrins bonded to a solid 
support (SS). The texaphyrin R groups and M may be those 
described for structure I. In structures II and III, X represents 
the group of the texaphyrin for use in bonding and Y 
represents the group of the matrix solid-support (SS) for use 
in bonding; XY thus represents the linker between a texa 









The matrix-supported texaphyrins of the present inven 
tion are useful for ester bond hydrolysis, heterogeneous 
catalysis, anion binding, separation of molecules such as 
nucleotides and oligonucleotides, magnetic resonance imag 
ing, photodynamic therapy, or DNA photocleavage, for 
example. 
An embodiment of the present invention is a method for 
separating a first molecule from a mixture of at least two 
molecules. The method comprises the step of contacting a 
matrix-supported texaphyrin metal complex with the mix 
ture to separate the first molecule. A further embodiment is 
a method for hydrolysing a phosphate ester, the method 
comprising the step of contacting a matrix-supported texa 
phyrin metal complex where the metal cation has catalytic 
activity for ester bond hydrolysis in aqueous solution with 
the phosphate ester to cleave the ester. A method for con 
ducting a chemical reaction catalyzed by a lanthanide metal 
cation is also an aspect of the present invention. This method 
comprises the step of contacting a matrix-supported texa 
phyrin lanthanide metal complex with a composition com 
prising the substrates for the chemical reaction. Matrix 
supported texaphyrins are further useful as a medical device, 
such as a catheter, implant, interface or artificial joint. 
Another embodiment of the present invention is a method 
of magnetic resonance imaging of a subject. The method 
comprises administering a matrix-supported texaphyrin 
paramagnetic metal complex to the subject; and imaging the 
subject by reference to the matrix-supported texaphyrin 
paramagnetic metal complex. 
A method of light-induced singlet oxygen production is 
also as aspect of the present invention. This method com 
prises subjecting a matrix-supported texaphyrin to light in 
the presence of oxygen. The texaphyrin is a photosensitive 
texaphyrin, i.e., either unmetallated or complexed with a 
diamagnetic metal. In further applications of the photosen 
sitivity of texaphyrins, the present invention also includes a 
method of photodynamic tumor therapy comprising, i) con 





suspected of having tumor cells, and ii) photoirradiating the 
matrix-supported texaphyrin in contact with the composi 
tion; and a method for deactivating a retrovirus or an 
enveloped virus comprising, i) contacting a matrix-sup 
ported texaphyrin with a composition suspected of having a 
retrovirus or enveloped virus, and ii) photoirradiating the 
matrix-supported texaphyrin in contact with the composi 
tion. 
A further aspect of the present invention involves the 
realization that novel expanded porphyrins, and particularly, 
texaphyrin structures may be prepared through the construc 
tion of polymers and oligomers, generically referred to as 
"multimers.” As used herein, the terms “multimer' is 
intended to refer to any compound that includes at least two 
texaphyrin macrocycles joined covalently. The terms "oli 
gomer' and "polymer' are generally understood to be over 
lapping in terms of defining a given length. However, it will 
still be appreciated that a texaphyrin "oligomer or "oligo 
texaphyrin refers to structures having about 2 or 3, and 
more preferably, about 10, 15, 20 or 30 texaphyrin units per 
molecule, up to and including about 40 or 50 units. On the 
other hand, "polymers' and "polytexaphyrin' are texaphy 
rincontaining structures that generally have upwards of 
about 40 or 50 texaphyrin units, up to an including about 80, 
100 or 150 texaphyrin units, or even up to about 200 
texaphyrin units or even more. 
The texaphyrin oligomers and polymers of the invention 
also include texaphyrin dimers and trimers. The various 
texaphyrin oligomers and polymers encompassed by the 
present invention are represented by, for example, polymers 
in which n, the number of individual texaphyrin derivative 
units, may be about 5, 10, 20, 30 or 40, for texaphyrin 
oligomers, and about 50, 75, 100, 150 or about 200 or so for 
texaphyrin polymers. 
In yet still further embodiments, the invention concerns 
compositions that are composed of a texaphyrin derivative 
in accordance with any one of the embodiments discussed 
above, particularly the polymer-supported texaphyrin, com 
plexed to a second compound. 
In still further embodiments, the invention concerns a 
method for forming a complex between a texaphyrin deriva 
tive and a second compound, wherein the method involves 
preparing a texaphyrin derivative as described above, 
including the polymer-supported forms such as silica-, Mer 
rifield resin-, glass-, plastic- and organic polymer-supported 
texaphyrins; obtaining the second compound; and contact 
ing the texaphyrin derivative with the second compound 
under conditions effective to allow the formation of a 
complex between the texaphyrin derivative and the second 
compound. 
DETALED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
Structure I provides a texaphyrin having substituent 
groups, R-R-2. A variety of texaphyrin derivatives and their 
metal complexes have been prepared, for example, as 
described in U.S. Pat. Nos. 4,935,498, 5,162,509, 5,252,720, 
5,292,414, 5,272,142, 5.256,399 and 5,369,101; PCT pub 
lications WO 94/09003 and WO/94,29316 and application 
Ser. Nos. 07/964,607, 08/015,208, 08/098,514,08/100,093, 
08/112,871, 08/112,786, 08/112,872, 08/135,118, 08/196, 
964, 08/207,845, 08/227,370 and 08/310,501, each of which 
is incorporated herein by reference. A texaphyrin in accor 
dance with any of the above-named references may be 














With reference to structure I, M may be hydrogen, a 
divalent metal cation or a trivalent metal cation, and R-Ra, 
R, and Rs may be separately and independently hydrogen, 
halide, hydroxyl, alkyl, alkene, alkyne, aryl, haloalkyl, nitro, 
formyl, acyl, hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, gly 
col, polyglycol, thiol, thioalkyl, aminoalkyl, alkoxyalkyl, 
aryloxyalkyl, alkyloxycarbonyl, aryloxycarbonyl, aldehyde, 
ether, ketone, carboxylic acid, saccharide, phosphate, phos 
phonate, sulfate, phosphate substituted alkyl, phosphonate 
substituted alkyl, sulfate substituted alkyl, carboxy, carboxy 
alkyl, carboxyamidealkyl, a nucleobase, modified nucleo 
base, oligonucleotide, antibody, hormone, amino acid, pep 
tide, polypeptide, a peptide having affinity for a biological 
receptor, a sugar, sugar derivative, polysaccharide, alkylat 
ing agent, steroid, Steroid derivative, one or more Sapphy 
rins, rubyrins, texaphyrins or derivatives thereof, or a couple 
that is coupled to an oligonucleotide, an antibody, a hor 
mone, a peptide having affinity for a biological receptor or 
a sapphyrin molecule; R and R may be independently 
selected from the groups of R-R, R and Rs, with the 
proviso that the halide is other than iodide and the haloalkyl 
is other than iodoalkyl, and Rs and Ro-R2 may be inde 
pendently hydrogen, alkyl, aryl, hydroxyalkyl, oxyalkyl, 
oxyhydroxyalkyl, carboxyalkyl, carboxyamidealkyl or a 
couple that is coupled to a saccharide, an oligonucleotide, an 
antibody, a hormone, a peptide having affinity for a biologi 
cal receptor, or a Sapphyrin molecule. 
M may be a divalent metallic cation, such as Ca(II), 
Mn(II), Co(II), Ni(II), Zn(II), CdCII), Hg(II), Sm(II), Fe(II), 
Cu(II), or UO(II), with “a” being 1; or M may be a trivalent 
metal cation, such as Mn(III), Co(III), Ni(III), Fe(III), 
Ho(III), Ce(III), Y(III), In(III), Pr(III), Nd(III), Sm(III), 
Sc(III), Eu(III), Gd(III), Tb(III), Dy(III), Er(III), Tm(III), 
Yb(III), Lu(III), La(III), or U(III); in which case, “a” would 
be 2. Representative paramagnetic metal cations are Sm(III), 
Eu(III), Gd(III), and Dy(III). Representative diamagnetic 
metal cations are La(III), Lu(III), and Y(III). As would be 
apparent to one skilled in the art, the charge “a” would be 
adjusted so as to account for the choice of metal, M, the pH 
under consideration, and the substituents R-R-2. For 
instance, if R =carboxyl and R-R-alkyl and the metal, 
M=Gd(III), and the solution is pH=7 (so that R=CO), the 
charge “a” would be zero. The charge would be negative 
when substituents have a sufficient number of negative 
charges, for example, when a substituent is an oligonucle 
otide. The charge would be +5, for example, when the M is 
Gd(III) and the net charge of a substituent(s) is three positive 
charges. 
In the texaphyrins represented by structure I, R, R2, R, 
R and Rs may be attached via a carbon-carbon or a 
carbon-oxygen bond. Also, where oxyhydroxyalkyl groups 
are present, they may be further substituted, bearing a 
substituent in lieu of hydrogen of the hydroxyl substituent. 
Additionally, where carboxyamidealkyl groups are present, 
they may have a secondary or tertiary amide linkage. 
The aryl group may be phenyl, or a phenyl having a nitro, 
carboxy, sulfonic acid, hydroxy, oxyalkyl or a halide sub 
stituent. Oxyhydroxyalkyls may be alkyls having indepen 
dently hydroxy substituents and ether branches. Carboxy 
alkyl groups may be alkyls having a carboxyl substituted 
ether, an amide substituted ether or a tertiary amide removed 
from an ether. Couples may be amide, thiol, thioether or 
ether covalent bonds. 
Representative examples of alkanes useful as alkyl group 
substituents of the present invention include methane, 
ethane, straight-chain, branched or cyclic isomers of pro 
pane, butane, pentane, hexane, heptane, octane, nonane and 
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decane, with methane, ethane and propane being preferred. 
Representative examples of alkenes useful as alkenyl group 
substituents include ethene, straight-chain, branched or 
cyclic isomers of propene, butene, pentene, hexene, heptene, 
octene, nonene and decene, with ethene and propene being 
preferred. Representative examples of alkynes useful as 
alkynyl group substituents include ethyne, straight-chain, 
branched or cyclic isomers of propyne, butyne, pentyne, 
hexyne, heptyne, octyne, nonyne and decyne, with ethyne 
and propyne being preferred. Representative examples of 
substituted alkyls include alkyls substituted by two or more 
functional groups as described herein. 
Among the halide substituents, chloride, bromide, fluo 
ride and iodide are contemplated in the practice of this 
invention with the exception of iodide for R and R. R. and 
R may have chloride, bromide or fluoride substituents. 
Representative examples of haloalkyls used in this invention 
include halides of methane, ethane, propane, butane, pen 
tane, hexane, heptane, octane, nonane and decane, with 
halides, preferably chlorides or bromides, of methane, 
ethane and propane being preferred. 
Representative examples of hydroxyalkyls include alco 
hols of methane, ethane, straight-chain, branched or cyclic 
isomers of propane, butane, pentane, hexane, heptane, 
octane, nonane and decane, with alcohols of methane, 
ethane or propane being preferred. "Hydroxyalkyl” is meant 
to include glycols and polyglycols; diols of ethane, straight 
chain, branched or cyclic isomers of propane, butane, pen 
tane, hexane, heptane, octane, nonane and decane, with diols 
of ethane or propane being preferred; polyethylene glycol, 
polypropylene glycol and polybutylene glycol as well as 
polyalkylene glycols containing combinations of ethylene, 
propylene and butylene. 
Representative examples of oxyalkyls include the alkyl 
groups as herein described having ether linkages. The num 
ber of repeating oxyalkyls within a substituent may be up to 
100, preferably is from 1-10, and more preferably, is 2-3. A 
preferred oxyalkyl is O(CH2CH2O), CH, where x=1-100, 
preferably 1-10, and more preferably, 2-3. 
Representative examples of thioalkyls include thiols of 
ethane, thiols of straight-chain, branched or cyclic isomers 
of propane, butane, pentane, hexane, heptane, octane, 
nonane and decane, with thiols of ethane (ethanethiol, 
CHSH) or propane (propanethiol, CHSH) being pre 
ferred. Sulfate substituted alkyls include alkyls as described 
above substituted by one or more sulfate groups, a repre 
sentative example of which is diethyl sulfate ((CH3)2SO); 
they also include simple anionic sulfate or sulfonate sub 
stituents such as -CH3SO-. 
Representative examples of phosphates include phosphate 
or polyphosphate groups. Representative examples of phos 
phate substituted alkyls include alkyls as described above 
substituted by one or more phosphate or polyphosphate 
groups. Representative examples of phosphonate substituted 
alkyls include alkyls as described above substituted by one 
or more phosphonate groups. 
Representative examples of carboxy groups include car 
boxylic acids of the alkyls described above as well as aryl 
carboxylic acids such as benzoic acid. Representative 
examples of carboxyamides include primary carboxyamides 
(CONH2), secondary (CONHR) and tertiary (CONR'R") 
carboxyamides where each of R and R" is a functional 
group as described herein. 
Representative examples of useful amines include a pri 














Representative examples of useful oligonucleotides 
include nucleotides, oligonucleotides and polynucleotides 
primarily composed of adenine, cytosine, guanine, thymine 
or uracil bases. It is understood that the term nucleotide as 
used herein refers to both naturally-occurring and synthetic 
nucleotides, poly- and oligonucleotides and to analogs and 
derivatives thereof such as methylphosphonates, phosphot 
riesters, phosphorothioates and phosphoramidates. 
Representative examples of useful steroids include any of 
the steroid hormones of the following five categories: 
progestins (e.g. progesterone), glucocorticoids (e.g., corti 
sol), mineralocorticoids (e.g., aldosterone), androgens (e.g., 
testosterone) and estrogens (e.g., estradiol). 
Representative examples of useful amino acids of pep 
tides or polypeptides include amino acids with simple ali 
phatic side chains (e.g., glycine, alanine, valine, leucine, and 
isoleucine), amino acids with aromatic side chains (e.g., 
phenylalanine, tryptophan, tyrosine, and histidine), amino 
acids with oxygen and sulfur-containing side chains (e.g., 
serine, threonine, methionine, and cysteine), amino acids 
with side chains containing carboxylic acid or amide groups 
(e.g., aspartic acid, glutamic acid, asparagine, and 
glutamine), and amino acids with side chains containing 
strongly basic groups (e.g., lysine and arginine), and proline. 
Representative examples of useful peptides include any of 
both naturally occurring and synthetic di-, tri-, tetra-, pen 
tapeptides or longer peptides derived from any of the above 
described amino acids (e.g., endorphin, enkephalin, epider 
mal growth factor, poly-L-lysine, or a hormone). Represen 
tative examples of useful polypeptides include both natu 
rally occurring and synthetic polypeptides (e.g., insulin, 
ribonuclease, and endorphins) derived from the above 
described amino acids and peptides. 
Hydroxyalkyl means alkyl groups having hydroxyl 
groups attached. Oxyalkyl means alkyl groups attached to an 
oxygen. Oxyhydroxyalkyl means alkyl groups having ether 
or ester linkages, hydroxyl groups, substituted hydroxyl 
groups, carboxyl groups, substituted carboxyl groups or the 
like. Saccharide includes oxidized, reduced or substituted 
saccharide; hexoses such as D-glucose, D-mannose or D-ga 
lactose; pentoses such as D-ribulose or D-fructose; disac 
charides such as sucrose, lactose, or maltose, derivatives 
such as acetals, amines, and phosphorylated sugars, oli 
gosaccharides, as well as open chain forms of various 
sugars, and the like. Examples of amine-derivatized sugars 
are galactosamine, glucosamine, sialic acid and D-glucam 
ine derivatives such as 1-amino-1-deoxysorbitol. Carboxya 
midealkyl means alkyl groups with hydroxyl groups, sec 
ondary or tertiary amide linkages or the like. Carboxyalkyl 
means alkyl groups having hydroxyl groups, carboxyl or 
amide substituted ethers, ester linkages, tertiary amide link 
ages removed from the ether or the like. 
For the above-described texaphyrins, oxyhydroxyalkyl 
may be alkyl having independently hydroxy substituents and 
ether branches or may be Co-Ho-1 O.O, or OCo 
x)H22OO, where n is a positive integer from 1 to 10, 
X is zero or a positive integer less than or equal to n, and y 
is zero or a positive integer less than or equal to ((2n+1)-2x). 
The oxyhydroxyalkyl or saccharide may be CH 
aOR OCH2O,R or (CH2)COR where n is a 
positive integer from 1 to 10, y is zero or a positive integer 
less than ((2n+1)-q), q is zero or a positive integer less than 
or equal to 2n+1, R" is independently H, alkyl, hydroxy 
alkyl, Saccharide, Con-Hon 1-2O, O, O2CCon 
w)Hccan-1-2OwO. Or N(R)OCCon-Hicom 1-2O, O, 
where m is a positive integer from 1 to 10, w is zero or a 
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positive integer less than or equal to m, Z is Zero or a positive 
integer less than or equal to ((2m+1)-2w), R is H, alkyl, 
hydroxyalkyl, or C.Hon. O.R, where m is a positive 
integer from 1 to 10, Z is zero or a positive integer less than 
((2m+1)-r), ris Zero or a positive integer less than or equal 
to 2m+1, and R is independently H, alkyl, hydroxyalkyl, or 
Saccharide. 
Carboxyamidealkyl may be alkyl having secondary or 
tertiary amide linkages or (CH2)CONHR', 
O(CH),CONHR, (CH2)CONCR), O 
O(CH2)CONCR), where n is a positive integer from 1 to 
10, R is independently H, alkyl, hydroxyalkyl, saccharide, 
Con-whic(2n+1)-2O.O. O2CCom whic(2m+1)-2.O.O. O 
N(R)OCC H22OO, where m is a positive 
integer from 1 to 10, w is zero or a positive integer less than 
or equal to m, Z is zero or a positive integer less than or equal 
to ((2m+1)-2w), R is H, alkyl, hydroxyalkyl, or C.H. 
1)--OR where m is a positive integer from 1 to 10, Z is 
Zero or a positive integer less than ((2m+1)-r), r is Zero or 
a positive integer less than or equal to 2m+1, and R is 
independently H, alkyl, hydroxyalkyl, or saccharide. 
The carboxyalkyl may be alkyl having a carboxyl substi 
tuted ether, an amide substituted ether or a tertiary amide 
removed from an ether or CH2O,R or OCH2. 
1)-OR where n is a positive integer from 1 to 10; y is 
Zero or a positive integer less than ((2n+1)-q), q is zero or 
a positive integer less than or equal to 2n+1, R is 
(CH),CO.R., (CH),CONHR or (CH2)CONCR), where 
n is a positive integer from 1 to 10; R is independently H, 
alkyl, hydroxyalkyl, Saccharide, Con-H(21-2O, O, 
O2CCon-whic2n+1)-2O.O. or N(R)OCCon-Hcc2n+1)- 
2w)OO, where m is a positive integer from 1 to 10, w is 
Zero or a positive integer less than or equal to m, Z is Zero 
or a positive integer less than or equal to ((2m+1)-2w), R is 
H, alkyl, hydroxyalkyl or C.H.O.R, where m is a 
positive integer from 1 to 10, Z is zero or a positive integer 
less than ((2m+1)-r), r is zero or a positive integer less than 
or equal to 2m+1, and R is independently H, alkyl, 
hydroxyalkyl, or saccharide. 
In structures II and III, X may be -(CH2) --NH2 
where n is an integer from 0 to 20, OH, COH, Cl, Br, I, OH, 
NCO, NCS, NC, C=CH, CH=CH, MgCl, ZnCl, Li, a 
nucleotide or an oligonucleotide. These groups may be at 
any of the substituents, R-R, R or Rs, of the texaphyrin. 
The X group reacts with available groups, termed Y, present 
on, or previously inserted into, the polymeric or solid 
support matrix. Y in structures II and II may thus be 
-(CH)--OH where n is an integer from 0 to 20, NH, 
COH, Cl, Br, I, NCO, NCS, oxirane, C=CH, MgCl, ZnCl, 
Li, a nucleotide or an oligonucleotide. Conversely, X may 
have the hydroxyl group and Y may have the amino group. 
The combination of reactive groups, X and Y, may give rise 
to a polymer-supported texaphyrin in which the texaphyrin 
is joined to the polymeric or solid-support matrix via an 
ether, ester, amide, amine, carbamate, urea, -CH=CH-, 
-CEC-, -(CH)- where m is an integer from 1 to 20, 
functionalized alkyl or aryl bond or via an oligonucleotide or 
even a peptide. 
In all cases, the Solid-support may be silica, silica gel, 
amino-functionalized silica gel, alumina, clay, Zeolite, glass, 
controlled pore glass, montmorillonite, polystyrene, poly 
ethylene, polyacrylamide, polypropylene, polyamide, Mer 
rifield resin, Sepharose, agarose, polystyrene, polydivinyl 
benzene, cellulose, alginic acid, chitosan, chitin, 
polystyrene-benzhydrylamine resin, an acrylic ester poly 
mer, a lactic acid polymer, polyurethane, polyvinylchloride, 














organosilicone, a biocompatible ceramic, bioglass or sin 
tered hydroxyapatite. A preferred solid support is silica gel. 
Structures IV and V show examples of structures II and 
III, respectively, representing solid-supported texaphyrins 
linked to silica gel. In these examples, X=O(CH), where 




Suitable methods for use in synthesizing a variety of 
texaphyrins with different R groups will be known to those 
of skill in the art, in light of disclosures such as, e.g., U.S. 
Pat. Nos. 4935,498 and 5,252,720 and PCT/US 95/O1996. 
Each of the foregoing documents are incorporated herein by 
reference for the purpose of supplementing the present 
teaching as to the synthesis of texaphyrin and texaphyrin 
derivatives. 
The texaphyrin units for use in conjugating to a solid 
Support may also be dimers, trimers, oligomers or polymers 
of texaphyrins or texaphyrin derivatives alone, or may be 
dimers, trimers, oligomers or polymers of texaphyrins or 
texaphyrin derivatives in combination with other expanded 
porphyrins, such as sapphyrins or rubyrins. The texaphyrins 
may also be conjugated to other units, such as alkyl chains 
or nucleobases, prior to linking to a polymer or solid 
Support. 
The term a "texaphyrin-metal complex', as used herein, 
refers to an aromatic pentadentate expanded porphyrin ana 
log metal complex, that may have various appended func 
tional groups. A wide range of metals may be complexed 




trivalent metal cations of the lanthanide group or Lewis 
acidic cations. Examples of these include all of the lan 
thanide group with the exception of Pm(III), as represented 
by La(III), Nd(III), Sm(III), Sm(II), Gd(III), Tm(III), 
Lu(III), Eu(III) and Dy(III); and also Y(III), InCIII), Ce(III) 
and Sc(III). Further divalent and trivalent metallic cations 
that may be bound to a matrix-supported texaphyrin of the 
invention include Ca(II), Mn(II), Co(II), Ni(II), Zn(II), 
Cd(II), Hg(II), and Mn(III), Co(III), Ni(III), Fe(III), Cu(II), 
Ho(III), Pr(III), Tb(III), Er(III), Yb(III), with even V(III), 
Cr(II), and Cr(III) being possibilities for binding to texa 
phyrins. 
The choice of metal ion for complexing to a texaphyrin 
will generally be dependent upon the use or uses intended 
for the matrix-supported texaphyrin. For example, metal 
ions that have catalytic activity for ester bond hydrolysis, 
such as Eu(III) or Dy(III), would be used to create a 
matrix-supported metallotexaphyrin for use in RNA hydro 
lytic cleavage. 
Metal ions that have catalytic activity for hydrogenation 
and polymerization reactions, such as Sm(II), may be used 
to construct a matrix-supported metallotexaphyrin for use in 
heterogeneous catalysis. Also, by varying the metals, e.g., by 
changing from Gd(III) to Lu(III) or Ce(III), the texaphyrin 
compounds can be modified so as to have enhanced selec 
tivity for various different anions such as phosphates and 
carboxylates. 
Paramagnetic species, such as Gd(III), Cu(III), Sm(III), 
Eu(III), Dy(III), Ni(III), Co(II), Co(III), Fe(II) and Fe(III), 
and most preferably, Gd(III), that have utility in magnetic 
resonance imaging protocols are also useful metals for 
complexing with matrix-supported texaphyrins. 
The use of diamagnetic species, such as La(III), Y(III) or 
Lu(III), is also encompassed within the present invention; 
such matrix-supported texaphyrins would then be useful in 
photodynamic therapy. Lu(II) or La(III) derivatives would 
thus be preferred in applications, such as in vitro purging of 
virus and cancer cells from blood or other bodily fluids, 
where the photodynamic production of singlet oxygen is of 
predicative importance. Also, 'Y" and 'In" derivatives 
would be of preference in radiotherapeutic and diagnostic 
applications. 
However, in certain embodiments, the use of a texaphyrin 
that is not complexed to a metal ion is also contemplated. 
Such systems would be useful for the chromatography, 
capture and/or removal of metals, both on an analytical scale 
and an industrial one. These matrix-supported texaphyrins 
without central metal ions would thus provide an advantage 
in waste removal from, for instance, marine and agricultural 
environments. 
In synthesizing a matrix-supported texaphyrin, the texa 
phyrin may be conjugated to the matrix at virtually any R 
position and using a wide range of R groups. For example, 
with reference to Structures II and III, the X group of the 
texaphyrin may be -(CH2)--NH2 where n is an 
integer from 0 to 20, OH, COH, Cl, Br, I, OH, NCO, NCS, 
NC, CECH, CH=CH, MgCl, ZnCl, Li, a nucleotide or an 
oligonucleotide. These groups would be reacted with avail 
able groups, termed Y, present on, or previously inserted 
into, the polymeric or solid-support matrix (termed SS in 
structures II and III). Y in structures II and III may thus be 
-(CH2)--OH, NH, COH, Cl, Br, I, NCO, NCS, 
oxirane, C=CH, MgCl, ZnCl, Li, a nucleotide or an oligo 
nucleotide. The combination of reactive groups, X and Y, 
gives rise to a matrix-supported texaphyrin in which the 














via an ether, ester, amide, amine, carbamate, urea, 
-CH=CH-, -C=C-, -(CH2)- where m is an 
integer from 1 to 20, functionalized alkyl or aryl bond or via 
an oligonucleotide or even a peptide. 
Therefore, in selecting a polymeric or solid-support 
matrix, one would generally select one that comprises, or 
may be derivatized to comprise, a group that permits the 
formation of a covalent bond with a texaphyrin substituent. 
Groups such as aryl, silyl, siloxy, aminoaryl, amino, ami 
doaryl and silyloxy are examples of these. 
The linker between a texaphyrin and a matrix may also be 
described using the formula: T-(CH2)-A-(CH2)-B, 
wherein T is any texaphyrin macrocycle or derivative or 
conjugate thereof; B is the polymeric matrix or solid-support 
matrix; and n and m are zero or integers of less than or equal 
to 20, or more preferably, of less than or equal to 10. Using 
this analysis, A may be alkyl, aryl, oxy, sulfide, amide, 
carbonyl, alkenyl, alkynyl, halide, alkylhalide, arylhalide, 
arenyl, hydroxyalkyl, glycol, polyglycol, thiol, alkylthiol, 
substituted alkyl, phosphate, phosphonate, Sulfate, phos 
phate substituted alkyl or aryl, phosphonate substituted alkyl 
or aryl, sulfate substituted alkyl or aryl, carboxy, carboxya 
mide, ester, thiol-substituted carboxyamide, or derivatized 
carboxyamide. 
The functionailization of a polymeric matrix or solid 
support matrix may take any one of many forms, so long as 
the result is to derivatize the polymer or support so that a 
texaphyrin moiety may be attached or bonded to the support. 
In preferred embodiments, the polymeric or solid-support 
matrix will thus comprise, or will be derivatized to com 
prise, an aryl, silyl, siloxy, aminoaryl, amino, amidoaryl or 
silyloxy group, which group will form as a linking unit 
(linker) between the solid-support and the texaphyrin. 
Examples of linkages between the texaphyrin and the poly 
meric or solid-support matrix include: -(CH2)-(CH2)2- 
Si(R)-O-, -(CH2)-Si(R)-O-, and -(CH2)-Si 
(CH2)2O-, where R may be siloxy, alkyl, hydroxyl, alkoxy, 
or oxygen, for example. 
A variety of polymeric or solid-support matrices may be 
linked to a texaphyrin as disclosed herein. Although there is 
overlap in terminology, the polymers or matrices may be 
considered as inorganic polymers or matrices, organic poly 
mers, copolymers and biocompatible polymers, all of which 
can be functionalized by those skilled in the art of chemical 
synthesis. 
Examples of inorganic polymers or matrices include, for 
example, silica, silica gel, amino-functionalized silica gel, 
alumina, clay, zeolite, glass, controlled pore glass and mont 
morillonite, along with certain biocompatible materials. 
Certain examples of organic polymers include polystyrene, 
polyethylene, polyacrylamide, polypropylene, polyamides, 
Merrifield resin, sepharose, agarose, with copolymers being 
represented by polystyrene and polydivinylbenzene. 
Polysaccharides are another group of organic polymers. 
These include cellulose and alginic acid and amino-polysac 
charides, such as chitosan and chitin. In addition to amino 
functionalized natural polymers, man-made amino-function 
alized organic polymers are also contemplated, such as 
polystyrene-benzhydrylamine resin. 
In addition to certain natural organic polymers, other 
biocompatible polymers include, for example, polyurethane, 
polyvinylchloride, nylon, latex, silicone rubber, halogenated 
polyethylenes, such as polytetrafluoroethylene (PTFE) and 
other Teflon(E) materials, organosilicones, e.g., Silastic(R) 
materials, and even biocompatible ceramics. 
In terms of matrices for use in medical compositions and 
devices, these should be "biocompatible'. This means that 
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the matrix has all the features commonly associated with 
medical uses, in that it is in a form that does not produce an 
adverse, allergic or other untoward reaction when adminis 
tered to an animal or human subject. 
The choice of matrix material will differ according to the 
particular circumstances and the site of the body into which 
the device is to be inserted. Physical and chemical charac 
teristics, such as, e.g., biocompatibility, biodegradability, 
strength, rigidity, interface properties and even cosmetic 
appearance may be considered in choosing a matrix, as is 
well known to those of skill in the art. 
Non-biodegradable matrices will most often be employed 
in accordance with the polymer-supported texaphyrins, such 
as, sintered hydroxyapatite, bioglass, aluminates, or other 
bioceramic materials. Ceramic delivery systems are 
described in U.S. Pat. No. 4,596,574, incorporated herein by 
reference. Polymeric matrices that may also be employed 
include acrylic ester polymers and lactic acid polymers, as 
disclosed in U.S. Pat. Nos. 4,526,909, and 4,563,489, 
respectively, each incorporated herein by reference. 
Naturally, the polymeric or solid-support matrix that 
forms the supporting part of the matrix-supported texaphyrin 
will be chosen according to the intended function and use of 
the resultant composition. For example, silica gel may be 
used to prepare bonded, texaphyrin-substituted silica gels 
for formulation into columns for use in medium to high 
pressure applications, such as in analytical and preparative 
HPLC separation technology. Alternatively, for low pressure 
applications, organic polymer-based texaphyrins may be 
prepared, such as texaphyrin-substituted Merrifield resins. 
Also, a glass support such as a glass capillary tube, may be 
employed to prepare a glass-supported texaphyrin for use, 
e.g., in analytical capillary electrophoresis (CE). 
Further compositions of the invention include medical 
devices that comprise a texaphyrin linked to a surface of the 
device, for example, a catheter in which one or more 
texaphyrins are linked to a surface of the catheter, an 
orthopedic implant or interface or an artificial joint. Such 
implants themselves and functional parts of implants, such 
as, e.g., Surgical Screws, pins, and the like are encompassed. 
In preferred embodiments, it is contemplated that the surface 
or surfaces of a catheter, implant, or a portion thereof, such 
as a screw, will be coated with a metallotexaphyrin com 
plexed to a paramagnetic metalion, such as Cu(III), Ni(III), 
Co(II), Co(III), Fe(II) or Fe(III), and most preferably, 
Gd(III), prior to implantation. 
The range of matrix-supported texaphyrins contemplated 
by the present inventors, and described herein, extends to 
second and third generation compositions designed to sepa 
rate molecular and ionic species based upon further specific 
binding modes, in addition to the basic neutral entity or 
phosphate recognition provided by the metallotexaphyrin 
moiety. One particular example concerns matrix-supported 
texaphyrins that further comprise long chain alkyl groups, 
such as, those of the formula CH-(CH2), where n=1-20, 
such as, e.g., CH(CH2)7, CH3(CH2) or CH(CH2)7, and 
also groups such as CH3CONH, phenyl, naphthyl, substi 
tuted naphthyl, and the like, to impart hydrophobic and TE-Tt 
interaction separation capacity to the modified solid-support. 
A second example contemplated concerns the use of matrix 
Supported texaphyrin constructs that also comprise nucleo 
base structures and thus allow separation of nucleobase 
containing compounds on the basis of specific base-pairing 
interactions. 
It is contemplated that further modified matrix-supported 














appended texaphyrin moiety or the polymeric or solid 
support matrix itself. For example, in the case of texaphyrin 
nucleobase columns, a texaphyrin-nucleobase conjugate 
may be used in the initial synthesis, or alternatively, the 
nucleobase units may be later appended onto available 
groups of the texaphyrin or onto available groups of the 
solid-support itself. Where the addition of long chain alkyl 
groups is desired, it is contemplated that such groups will 
generally be introduced onto the surface of the polymeric or 
solid-support matrix, although the invention is not limited 
solely to this mode of addition. 
The range of matrix-supported texaphyrin-nucleobase 
constructs contemplated includes a wide variety of nucleo 
base compounds. The choice of compound will be tailored 
to suit the intended function of the solid-support, such as, to 
bind to a specific nucleobase-containing compound which 
one desires to purify, remove, or otherwise separate from a 
mixture of compounds. The nucleobase-containing group, 
whether bonded to the texaphyrin or to the support matrix, 
may therefore comprise any purine or pyrimidine base 
including adenine, cytosine, guanine, thymidine, uridine and 
inosine, or any analog or derivative thereof, including anti 
metabolite nucleobases, nucleobase derivatives shown in 
Table 2, and even protected nucleobases. 
The texaphyrin-nucleobase solid-support matrices may 
also have appended nucleosides, nucleotides and oligonucle 
otides, for example, oligonucleotides comprising between 
two and about 10 nucleobase units. Constructs bearing a 
selected nucleotide or oligonucleotide may be formulated 
into columns, filters or other solid materials such as capillary 
tubes, and used to selectively bind compounds which 
include the complementary nucleotide or oligo or poly 
nucleotides containing substantially complementary 
sequences. As used herein, a substantially complementary 
sequence is one which the nucleotides generally base pair 
with the complementary nucleotide and in which there are 
very few base pair mismatches. 
Matrix-supported texaphyrins of the second and third 
generation may also comprise functional groups designed to 
alter the chemical capabilities of the metallotexaphyrins. For 
example, the texaphyrin may include an imidazole ring or an 
arginine residue. The texaphyrin may also have an attached 
chiral group, for example: a D-sugar unit, such as D-glu 
copyranosyl, an L-Sugar unit, an L-amino acid, such as 
L-alanine or L-phenylalanine; an oligopeptide; an oligosac 
charide, or a chiral binaphthyl system. 
Although described in terms of texaphyrins, the present 
invention also encompasses other matrix-supported 
expanded porphyrins, including sapphyrins and rubyrins, 
that have been joined to a polymeric or solid-support matrix. 
The use of an expanded porphyrin capable of binding 
anions, and preferably, those capable of phosphate or nitrate 
chelation, is particularly contemplated. In such embodi 
ments, the use of expanded porphyrins of the rubyrin class, 
and particularly of the sapphyrin class, is envisioned. 
The synthesis of rubyrin and derivatives thereof is 
described in detail in U.S. patent application Ser. No. 
08/015,208, incorporated herein by reference. Polymer-sup 
ported rubyrins may be prepared using a rubyrin compound 
as the starting material in combination with the synthetic 
methodology disclosed in the present application. In other 
embodiments, the invention also provides for the generation 
of polymer-supported sapphyrins comprising a sapphyrin 
unit, derivative, conjugate or polymer thereof linked to a 
support. In addition to the present application, the generation 
of polymer-supported sapphyrins is described in PCT pub 
lication WO94/09003, incorporated herein by reference. 
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The present invention also provides methods for using the 
matrix-supported texaphyrins and expanded porphyrins 
described above in separating a first molecule from a mix 
ture of at least two molecules. In the present sense, the term 
"molecule' is being used for simplicity to refer to both 
molecular and atomic structures and thus encompasses spe 
cies such as metal cations like those of the trivalent lan 
thanide series and atomic anions such as Cl, Br, and I. 
The columns, capillary tubes, filters, devices and the like, of 
the invention are contemplated to be of most use in sepa 
rating neutral or negatively-charged entities that would be 
bound as ligands to the texaphyrin metal centers. Such 
species could be neutral materials containing, e.g., 
hydroxyls; or anionic materials, such as those bearing a 
phosphate, phosphonate, phosphate ester, arsenate, arsenate 
ester, carboxylate, nitrate, sulfate, sulfonate or sugar moiety 
within their structure. 
However, it is envisioned that the matrix-supported texa 
phyrin constructs will generally be of most use for separat 
ing oligonucleotides such as RNA and DNA that contain 
phosphate esters. Here, in addition to the separation embodi 
ment, it is contemplated that these same solid-supports could 
be used to effect catalytic hydrolysis of the phosphate ester 
bonds, as described in the present detailed examples. 
To separate a first molecule, such as an RNA fragment of 
a given length from a mixture containing at least one other 
oligonucleotide of similar but not identical composition in 
accordance with the invention, one would generally contact 
a matrix support bearing a texaphyrin with the mixture, 
thereby separating the first molecule. The contacting may, 
generally, take the form of passing a solution containing the 
mixture to be separated, or purified, over a column to which 
texaphyrins are appended. 
The separation process generally entails binding the mix 
ture containing the molecules or species to be separated to 
a matrix-supported texaphyrin, such as a column, capillary 
tube, filter, filter cartridge or such like, and then, subse 
quently, removing, or eluting, the bound species in such a 
way as to result in the formation of distinct fractions 
containing molecules which have been separated from each 
other. 
The phrases "separated” and "purified" in this context are 
intended to mean separated away from, and purified relative 
to, the degree of purity of an individual molecule, atom or 
species in the original composition. Although it is contem 
plated that the methods of the invention may be employed to 
achieve high resolution separation of, e.g., oligonucleotides, 
there is no requirement that such high degrees of purity 
always be achieved. Separation methods that result in less 
substantially separated species also have utility and are thus 
encompassed by the claimed invention. 
The methods for separating or purifying anionic, cationic, 
or even neutral species by contacting solutions of various 
mixtures with a functionalized solid-support are generally 
encompassed by the terms "chromatographic or electro 
phoretic separation methods'. The chromatographic meth 
ods are those using columns, such as HPLC columns, 
whereas the electrophoretic separation methods are exem 
plified by those using capillary tubes. Various chromato 
graphic and electrophoretic separation techniques are well 
known in the art, and any such method may be employed in 
connection with the invention simply by preparing a poly 
mer-supported texaphyrin and packaging or formulating it to 
give a device to be used as the central component of the 
separation technique. 
In separating anionic, cationic or even neutral species, 














contemplated that one would generally first formulate the 
mixture to be separated into a solution. One would then 
contact the matrix-supported texaphyrin with the solution 
under conditions effective, and for a time period sufficient, 
to allow binding of the anionic, cationic or neutral species to 
the solid-support. This is straightforward and may be 
achieved simply by passing the solution over the solid 
material with or without the use of pressure or an electro 
static field. The anionic or neutral species will, in the 
simplest case, bind specifically to the metal center of the 
texaphyrin moiety. Where the matrix-supported texaphyrins 
bear other groups, such as long chain alkyl groups, nucleo 
bases, or aromatic residues, other portions of the contem 
plated substrates, such as hydrophobic portions or purine 
and pyrimidine nucleobase substituents in this case, e.g., of 
oligonucleotides will also likely specifically bind to these 
additional functional groups or interact with the texaphyrin 
ring. 
Suitable conditions effective to allow binding of the 
species to the solid-support will be chosen based upon 
considerations such as the number and type of the particular 
species to be separated, the purity of the resultant compo 
sitions desired, the particular type of texaphyrin and its 
complexed metal ion, other functional groups appended to 
the texaphyrin or to the solid-support matrix, and the like. 
After the initial binding stage, the solid-support may be 
washed with the same or other buffers of chosen stringency 
and for varying periods of time to remove any non-specifi 
cally bound species from the solid-support. 
The matrix-supported texaphyrin with the bound species 
would next generally be treated to remove the bound species 
that may then be collected in a more separate and purified 
form than when applied, for example, collected in distinct 
fractions. This process will generally be achieved by wash 
ing the solid-support with a second solution effective to 
detach the bound anionic or neutral species, i.e., a solution 
effective to disrupt the specific binding between the species 
and the texaphyrin, metal center or between it and other 
functional groups incorporated within the texaphyrin struc 
ture or the support. Such separations, in the case of chro 
matographic applications would be useful both for analysis 
and purification procedures. In the case of capillary electro 
phoresis, however, they would be likely to be useful only for 
analysis. 
The second solution will be distinct from that first used 
and, again, will be chosen based upon the particular appli 
cation. It may, for example, have a different ionic strength, 
hydrophobicity or pH compared to the first solution and may 
contain different concentrations of salt or other chaotropic 
agents as desired. This removal process may be termed 
"elution' and the eluted material will generally be collected 
in relatively small fractions, such as in 1 to 2 ml fractions, 
and preferably in fractions of about 1 ml or smaller, so that 
the fractions contain one or more detached species that have 
been separated or purified away from the total number of 
species in the starting composition. Alternatively, for analy 
sis applications, the fractions could be much smaller, i.e. 
210 ul, and used only as a means of assessing by, e.g., 
optical absorbance, refractive index, or mass spectral frag 
mentation, the composition of a given fraction. From such 
an analysis one would then, in the usual way of the art, 
obtain a profile of the purity and composition of the original 
solution. 
Any of the matrix-supported texaphyrin derivatives 
described above may be used as a separating apparatus in 
this regard, as may supports comprising a sapphyrin or 
rubyrin derivative, and those including nucleobase conju 
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gates, long chain alkyl groups and oligonucleotides. 
Although a detailed understanding of the binding mecha 
nisms is not necessary in practicing the present invention, it 
should be noted that the use of a texaphyrin generally relies 
on substrate binding to a metal center, whereas Sapphyrin 
and rubyrin are based upon more direct anion chelation. 
Regardless of the particular expanded porphyrin, the 
separating apparatus may use, for example, silica gel, Mer 
rifield resins, glass, agarose or Sepharose, polyacrylamide or 
another type of plastic as the support matrices and may be 
prepared in virtually any solid form including columns, 
filters, cartridges, tubes and thin layers. Their use in ana 
lytical and preparative modes in both research and clinical 
laboratories is envisioned, as is their use in medical and 
veterinary procedures, including various diagnostic embodi 
netS. 
It is contemplated that these novel matrix-supported 
expanded porphyrins will be found to be particularly useful 
in separating compounds which have nitrate or phosphate 
groups or phosphate esters within their structure. This 
includes separating or purifying purine- and pyrimidine 
containing compounds, including nucleotides, oligonucle 
otides, gene fragments, nucleobase analogs, and derivatives 
such as antimetabolite purines and pyrimidines, e.g., AZT 
phosphate, dideoxycytidine phosphate, and other prodrugs 
used in the treatment of viral infections including HIV. The 
use of the methods and compositions of the invention in 
clinical analyses to distinguish active phosphorylated nucle 
otide analogs from naturally occurring phosphorylated prod 
ucts, such as AMP or GMP, is a further particular utility 
envisioned by the inventors. 
Organophosphorus compounds, nitrate esters, as well as 
simple inorganic nitrate, nitrite, phosphate and phosphonate 
anions, particularly pesticides, herbicides, fungicides, 
marine pollutants and even chemical warfare agents may 
also be separated in the manner of the invention. For 
example, using polymer-supported expanded porphyrin con 
structs is envisioned to be of use in removing various such 
undesirable compounds from contaminated solutions, e.g., 
in waste-removal and treatment regimens. 
As disclosed herein, nucleotide mono-, di- and tri-phos 
phates may be advantageously separated from each other 
using polymer-supported texaphyrins, as may mono-nucle 
otides, di-nucleotides and various length oligonucleotides, 
such as oligonucleotide probes and primers. The separation 
of larger polynucleotides, up to and including gene frag 
ments, genes, and antisense constructs is also encompassed 
by the present invention. The sequence-specific purification 
of nucleotide-containing constructs is also envisioned, 
whereby specific oligonucleotides or polynucleotides, 
whether DNA or RNA species, may be obtained by employ 
ing second or third generation matrix-supported expanded 
porphyrins bearing appended oligonucleotides with specific 
sequences. This allows the separation of nucleotides and 
oligonucleotides not only on the basis of charge and length 
but also on the basis of nucleic acid type. 
The present invention also provides methods for hydrol 
ysing a phosphate ester bond. These methods generally 
comprise contacting a matrix-supported metal-texaphyrin 
(metallotexaphyrin) complex with a composition compris 
ing one or more molecules or species that include within 
their structure a phosphate ester bond, in order to cleave said 
phosphate ester. This process generally takes the form of 
contacting the matrix-supported texaphyrin with a solution 
that includes the molecule(s) to be cleaved under conditions 














contact between the metal-complexed texaphyrin and the 
molecule. The functional interaction thus results in cleavage 
of the ester linkage. 
The use of matrix-supported texaphyrins allows facile 
recovery of the catalyst without the risk of substrate or 
product contamination by the catalyst. Flow reactions are 
also possible using these "heterogeneous systems'. These 
are therefore generally preferred over the batch processes 
possible with "homogeneous systems'. 
In such ester cleavage embodiments, the matrix-supported 
texaphyrin will be complexed to a metal ion, such as a 
divalent or trivalent metal cation, that has catalytic activity 
for ester bond hydrolysis, particularly in aqueous environ 
ments. Examples of useful metals that may be complexed 
with a texaphyrin in this manner are La(III), NdCIII), 
Sm(III), Gd(III), Tm(III), Lu(III), Eu(III), Dy(III), Y(III) 
and InCIII); with Eu(III)- and Dy(III)-complexed texaphy 
rins being preferred in certain embodiments as these texa 
phyrin-metal complexes are particularly effective in medi 
ating RNA cleavage. 
Various biologically important phosphate esters may be 
hydrolyzed, or cleaved, according to the methods of the 
present invention, including phosphate monoester, diester 
and even triester linkages. Exemplary ester bonds that may 
be cleaved using matrix-supported texaphyrins are those 
present within physiologically important molecules, such as, 
nucleic acids, including, RNA from viral, bacterial and other 
pathogenic sources, as well as nucleic acid transcripts from 
oncogenes; mediators of metabolism, e.g., nucleotides such 
as ATP, ADP, AMP. cAMP, GTP, GDP, UDP, and cofactors 
such as NADH, NADPH, FAD, FADH and UDP-glucose; 
phospholipids, such as phosphatidylcholine and phosphati 
dylethanolamine; other phosphate anhydrides; and a wide 
variety of assay substrates, such as p-nitrophenylphosphate 
eSter. 
In further embodiments, the present invention also pro 
vides advantageous methods for conducting a chemical 
reaction catalyzed by a lanthanide metal. These methods 
generally comprise preparing a matrix-supported metallo 
texaphyrin complex in which the texaphyrin is complexed to 
a lanthanide metal, and contacting the matrix-supported 
metallotexaphyrin complex with a composition comprising 
the substrates for the lanthanide metal-catalyzed chemical 
reaction. "Contacting would generally be with a solution 
that includes the substrate molecule(s) for the reaction under 
conditions effective, and for a time period sufficient, to allow 
functional contact between the metal complexed texaphyrin 
and the molecule(s). Metallotexaphyrins complexed to 
La(III), Sm(III), Sm(II), Eu(III), Ce(III) or Dy(III) may be 
found to be particularly useful. These methods are suitable 
for the catalysis of reactions such as ester hydrolysis, amide 
hydrolysis, phosphate ester hydrolysis, acyl transfer, hydro 
genation and polymerization. 
Improved methods for MRI form another aspect of the 
invention, particularly as such methods may be used to 
locate a device or catheter within the body. In such methods, 
one would prepare a matrix-supported metallotexaphyrin 
complex comprising a paramagnetic metal ion, such as 
Gd(III), Cu(II), Ni(III), Co(II), Co(III), Fe(III) or Fe(III), 
then generally formulate this polymer-supported texaphyrin 
into a device and insert the device into an animal. By 
detecting the position of the paramagnetic metal ion within 
the animal, one would then be able to detect, monitor, adjust 
and/or retrieve the device. The use of Gd(III) is particularly 
preferred in such embodiments. 
In further aspects, the invention provides new methods for 
light-induced singlet oxygen production using matrix-Sup 
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ported texaphyrins, optionally, in combination with diamag 
netic metal cations such as Lu(II) or La(III). By subjecting 
a matrix-supported texaphyrin or texaphyrin diamagnetic 
metal complex to light in the presence of oxygen, singlet 
oxygen production is induced. 
This may be used as a method for photodynamic tumor 
therapy (PDT). Here, one would generally contact a matrix 
supported texaphyrin or texaphyrin diamagnetic metal com 
plex with a composition suspected of comprising tumor cells 
and then photoirradiate the composition as it is contacted 
with the matrix-supported texaphyrin or texaphyrin diamag 
netic metal complex. Photoirradiation is used in a sufficient 
quantity to induce singlet oxygen production at levels that 
are cytotoxic to the tumor cells. This is particularly suitable 
for use, ex vivo, in deleting tumor cells from the blood of 
patients that have, or are suspected to have, leukemia, so that 
the purged blood may be re-administered to the patient. 
Another method of exploiting singlet oxygen formation 
using a matrix-supported texaphyrin is to deactivate a ret 
rovirus or enveloped virus, such as HIV-1, HIV-2, HSV, SIV 
or FIV. Again, one would prepare a matrix-supported texa 
phyrin or matrix-supported texaphyrin diamagnetic metal 
complex; contact this with a composition suspected of 
comprising a retrovirus or enveloped virus; and then pho 
toirradiate the composition in contact with the matrix 
supported texaphyrin or texaphyrin diamagnetic metal com 
plex to produce singlet oxygen in a quantity cytotoxic to any 
virus. In this way, viruses may be removed from blood and 
blood products suspected of comprising retrovirus or envel 
oped virus. This is useful not only in terms of rendering 
blood free from virus for use in transfusions, but also for use 
in rendering blood products and sera free from virus for use 
as growth media, e.g., in monoclonal antibody generation. 
A further use of the matrix-supported texaphyrins 
involves the discovery that photosensitive texaphyrins cata 
lyze the cleavage of a polymer of deoxyribonucleic acid. 
Cleavage is enhanced by the presence of oxygen, indicating 
that singlet oxygen or another oxygen by-product is the 
likely toxic agent. A photosensitive texaphyrin may be a 
diamagnetic metal texaphyrin complex or may be metal 
free. The interaction between a matrix-supported texaphy 
rin-oligonucleotide conjugate and the complementary oli 
gonucleotide is an example of antisense technology and 
allows cleavage of a polymer of deoxyribonucleic acid that 
is in the vicinity of the specific binding. The inherent 
biolocalization properties of texaphyrin further effect target 
ing of an antisense agent to lipophilic regions, especially 
tumors and atheroma, for example. 
The term "texaphyrin-oligonucleotide conjugate” means 
that an oligonucleotide is attached to the texaphyrin in a 5' 
or 3' linkage or both types of linkages to allow the texaphy 
rin to be an internal residue in the conjugate. The oligo 
nucleotide or other site-directing molecule may be attached 
either directly to the texaphyrin via a linker, or a couple of 
variable length. During catalysis, for example, the texaphy 
rin portion of a texaphyrin metal complex-oligonucleotide 
conjugate is placed in the vicinity of the substrate upon 
binding of the oligonucleotide to the targeted nucleic acid 
substrate. A 'sapphyrinoligonucleotide conjugate' is 
referred to in the same way as described above for a 
texaphyrin-oligonucleotide conjugate except that the texa 
phyrin is replaced with a sapphyrin. 
A couple may be described as a linker, i.e., the covalent 
product formed by reaction of a reactive group designed to 
attach covalently another molecule at a distance from the 













amides, amine, thioether, ether, orphosphate covalent bonds 
as described in the examples for attachment of oligonucle 
otides. In most preferred embodiments, oligonucleotides and 
other site-directing molecules are covalently bonded to the 
texaphyrin via a carbon-nitrogen, carbon-sulfur, or a carbon 
oxygen bond. 
The cleavage of DNA described herein is a photolytic 
cleavage. It is believed that the cleavage is not hydrolyric 
where a water molecule is added across a bond to break the 
bond, nor is the cleavage believed to be solely oxidative 
where an oxidation reaction in the absence of light causes 
breakage of the bond. 
It will be apparent to one of skill in the art in light of the 
present disclosure that the site-specific cleavage of DNA has 
important ramifications in a variety of applications. Potential 
particular applications for this process include antisense 
applications; the specific cleavage and possible subsequent 
recombination of DNA, destruction of viral DNA, construc 
tion of probes for controlling gene expression at the cellular 
level and for diagnosis; and cleavage of DNA in footprinting 
analyses, DNA sequencing, chromosome analyses, gene 
isolation, recombinant DNA manipulations, mapping of 
large genomes and chromosomes, in chemotherapy and in 
site-directing mutagenesis. 
The term "photosensitive” means that upon irradiation, 
texaphyrin effects either the generation of oxygen products 
that are cytotoxic or means that the texaphyrin is fluorescent, 
or both. Cytotoxic oxygen products may be singlet oxygen, 
hydroxyl radicals, superoxide, or hydroperoxyl radicals. The 
texaphyrin may be a diamagnetic metal complex or a 
metal-free species. Diamagnetic metals would include pref 
erably, Lu(III), La(III), InCIII), Zn(II) or CdCI). Most pref 
erably, the diamagnetic metal is Lu(III). 
A further embodiment of the present invention provides a 
method of light-induced cleavage of a polymer of deoxyri 
bonucleic acid. The method comprises the steps of contact 
ing the polymer with a matrix-supported photosensitive 
texaphyrin and exposing the matrix-supported photosensi 
tive texaphyrin to light for a time sufficient to cleave the 
polymer. In a preferred embodiment, the exposing step is 
carried out in the presence of oxygen. The texaphyrin may 
be a metal complex of texaphyrin, preferred metals are 
diamagnetic metals. The polymer may be a solution or a 
suspension of DNA or may be cellular DNA in vitro or in 
vivo. DNA is preferably cleaved over RNA. 
Another embodiment of the present invention is a method 
for targeted intracellular DNA cleavage. The method com 
prises the introduction into a cell of a matrix-supported 
texaphyrin coupled to an oligonucleotide having comple 
mentary binding affinity for a targeted DNA, whereby 
cleavage of the targeted DNA is catalyzed by the matrix 
supported texaphyrin. The DNA may be oncogene DNA or 
may be normal DNA which needs to be destroyed, for 
example, due to improper timing of expression. The oligo 
nucleotide coupled to the matrix-supported texaphyrin may 
be DNA, a DNA analog, or an RNA analog oligonucleotide. 
The texaphyrin may be a free base texaphyrin or a metallated 
form of texaphyrin. The metal is preferably a diamagnetic 
metal, most preferably Lu(III). 
A method for inhibiting the expression of a gene in an 
animal comprising the administration to the animal of a 
matrix-supported texaphyrin oligonucleotide-conjugate is a 
further embodiment of the present invention. The oligo 
nucleotide may have complementary binding affinity for 
regulatory regions of the gene or for regions encoding exons 
or introns. The oligonucleotide may be complementary to 
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either strand of the DNA or to the duplex DNA. A further 
embodiment of the present invention is a method for inhib 
iting the expression of a gene in a particular tissue of an 
animal comprising administering to the animal a matrix 
supported texaphyrin having specificity for the tissue. The 
texaphyrin may have appended an oligonucleotide comple 
mentary to the target gene. 
A further embodiment of the present invention is a 
matrix-supported texaphyrin conjugate wherein two or more 
separate matrix-supported texaphyrin complexes are 
attached to an oligonucleotide, one at the 3', one at the 5' end, 
and/or one or more at an internal residue. The texaphyrin 
may be metal free or may be metallated. A metal ion of each 
of the matrix-supported texaphyrin complexes may be the 
same or it may be different. Similarly, each of the matrix 
supported texaphyrins may be different. Use of a dual 
texaphyrin complex-conjugate should effect the cleavage of 
DNA with increased efficiency due to the concerted activity 
of the metal complexes. For diagnosis and treatment pur 
poses, the administration of such a matrix-supported conju 
gate with one texaphyrin complex having a diamagnetic 
metal species and the other having a paramagnetic species 
would allow binding, imaging, and cleavage, all effected by 
one conjugate. In this case, binding is effected by the 
oligonucleotide, imaging is accomplished by MRI due to the 
presence of the paramagnetic metal ion, and cleavage is 
accomplished by the photosensitive texaphyrin containing a 
diamagnetic metal cation. Therefore, the biodistribution and 
cellular penetration of the matrix-supported conjugate may 
be determined. 
In terms of apparatus for use in phosphate ester cleavage, 
catalysis, ex vivo PDT, and DNA photocleavage, it is 
contemplated that the matrix-supported texaphyrins may be 
formulated into various columns, including HPLC columns; 
capillary electrophoresis tubes; and various other devices 
such as filters and large reaction vessels. 
Although the present invention generally concerns poly 
meric matrices or solid-supports linked to texaphyrins, in 
certain other embodiments the invention provides for the 
linkage of further groups to a texaphyrin. TheSe include, for 
example, Sugars, Sugar derivatives, polysaccharides, metal 
chelating groups, alkylating agents, nucleobases, modified 
nucleobases, oligonucleotides, antibodies, hormones, Ste 
roids, steroid derivatives, amino acids, peptides, polypep 
tides, other texaphyrins and texaphyrin derivatives, rubyrin 
and rubyrin derivatives, sapphyrins and Sapphyrin deriva 
tives, polymeric sapphyrins, polymeric texaphyrins, and the 
like. 
Other embodiments of the invention relate to expanded 
porphyrin, and particularly, texaphyrin derivatives that are 
polyhydroxylated and therefore water-soluble. Water 
soluble texaphyrins are particularly desirable where one 
would like to exploit the various surprising properties of 
these macrocycles in connection with human or animal 
applications. The nature of the polyhydroxylation is not 
believed to be particularly critical to achieving water solu 
bility of a texaphyrin derivative, so long as at least two 
hydroxyl groups per macrocycle are incorporated into the 
structure. This is similar to sapphyrins, where the present 
inventors have found that the introduction of at least 1 or 2 
hydroxyl groups per macrocycle was sufficient to achieve 
some degree of sapphyrin water solubility. This aspect of the 
invention is also important to the improved chromatographic 
and electrophoretic supports disclosed herein. 
One means for introducing hydroxyl groups into a texa 














alkyl substituents to the basic macrocyclic unit. Thus, exem 
plary polyhydroxylated texaphyrins are those that are 
modified to include structures such as hydroxymethyl, 
hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxy 
alkyl, trihydroxyalkyl, or the like, at one or more R positions 
of the basic structure. 
An alternative means of achieving polyhydroxylation is 
through the addition of sugar moieties such as a saccharide, 
polysaccharide, saccharide derivative or aminosaccharide, 
to the texaphyrin macrocycle structure. In an analogous 
case, it has been found that the addition of a single saccha 
ride molecule to a sapphyrin macrocycle achieves a degree 
of water solubility. These structures are referred to broadly 
herein as texaphyrin- and Sapphyrin-sugar compounds, con 
jugates or derivatives. 
The nature of the sugar is not critical to the achievement 
of water solubility, and a non-exhaustive, exemplary list of 
sugars contemplated to be useful in this regard is set forth in 
Table 1. Of course, any sugar or modified sugar may be 
employed including sugars having additional phosphate, 
methyl or amino groups and the like. Moreover, the use of 
both D- and L-forms, as well as the O. and B forms is also 
contemplated. However, it is contemplated that preferred 
sugars for use in accordance herewith will include, for 
example, glucose, glucosamine, galactose, galactosamine 
and mannose. 
TABLE 1. 











Galactose Sialic Acid 
Talose Chitosan 
Ribulose Alginic Acid 
Xylulose 
Psicose 
For hydrolyzing nucleic acids, such as RNA, using a 
texaphyrin derivative, it is currently preferred to use a 
Eu(III)-texaphyrin, and most preferably a solid-supported 
Eu(III)-texaphyrin. RNA cleavage using Eu(III)-texaphyrins 
and solid-supported Eu(III)-texaphyrins is described herein 
in Example 14. 
In further embodiments, the present invention relates to 
what are referred to as expanded porphyrin, and particularly, 
texaphyrin-nucleobase conjugates. As used herein, the term 
"texaphyrin-nucleobase conjugate' is intended to refer 
broadly to any conjugate formed by the covalent conjugation 
of any texaphyrin macrocycle to any nucleobase. The texa 
phyrin-nucleobase conjugates may also be attached to poly 
meric matrices or solid-supports, such as silica gel, glass, 
Merrifield resins, polyacrylamide, polystyrene, sepharose, 
agarose, clays, Zeolites, plastics, biocompatible matrices and 
the like; to form a chromatography column, filter or medical 
device. 
As used herein, the term "nucleobase' is intended to refer 
broadly to any moiety that includes within its structure a 
purine or pyrimidine, a nucleic acid, nucleoside, nucleotide, 
or any derivative of any of these. Thus, the term nucleobase 
includes adenine, cytosine, guanine, thymidine, uridine, 
5,594,136 
23 
inosine, or the like, bases, nucleotides or nucleosides, as 
well as any base, nucleotide or nucleoside derivative based 
upon these or related structures. 
A particular example of useful nucleobases are the so 
called antimetabolites, which are generally based upon the 
purine or pyrimidine structures. These compounds typically 
exert their biological activity as antimetabolites through 
competing for enzyme sites and thereby inhibiting vital 
metabolic pathways. However, in the context of the present 
invention, the inventors are employing the term "antime 
tabolite nucleobase' quite broadly to refer to any purine or 
pyrimidine-based molecule that will effect an anticellular, 
antiviral, antitumor, antiproliferative or antienzymatic 
effect, regardless of the underlying mechanism. Exemplary 
structures are shown in Table 2, including preferred conju 
gates such as purine or pyrimidine antimetabolites such as 
FU, AraC, AZT, dd, ddC, xylo-GMP, Ara-AMP, PFA or 
LOMDP, and phosphorylated versions thereof. 
Preferred compounds for conjugating to a texaphyrin 
include naturally-occurring purine or pyrimidine nucleo 
bases, namely, cytosine, guanine, thymidine, adenine and 
uridine. Equally, such texaphyrin conjugates may include 
modified versions of any of these, such as the heterocyclic 
components of those nucleoside/nucleotide analogues listed 
in Table 2 and phosphorylated version of the compounds 
listed therein. 
TABLE 2 
























Also included within the invention are texaphyrin mono 
nucleobase derivatives including chemically modified 
nucleobase such as "protected” bases. Protecting groups are 
used to protect reactive groups, such as amino and carboxyl 
groups, from inappropriate chemical reactions. Texaphyrin 
nucleobase conjugates with protected bases include, for 
example, conjugates wherein one or more base has a pro 
tecting group, such as 9-fluorenylmethylcarbonyl, benzy 
loxycarbonyl, 4-methoxyphenacyloxycarbonyl, t-butyloxy 
carbonyl, 1-adamantyloxycarbonyl, benzoyl, 
N-triphenylmethyl or N-di-(4-methoxyphenyl)phenylm 














Conjugation of a nucleobase to a texaphyrin derivative to 
form a mononucleobase texaphyrin conjugate may be via 
any of the R groups shown in Structure I. Conjugation of the 
two separate nucleobases to a texaphyrin derivative to form 
a dinucleobase texaphyrin conjugate may also be via any 
two of these R groups. Any of the texaphyrin mono-, di-, or 
oligo-nucleobase conjugates and derivatives, including both 
naturally-occurring nucleobases and modified nucleobases, 
may also be linked to a solid-support to form a matrix 
supported texaphyrin composition. 
In synthesizing nucleobase conjugates by the condensa 
tion of texaphyrin mono- and bis-acids with conveniently 
modified nucleobases, various spacers may be used. These 
include, for example, oligomethylene bridges with terminal 
amino, or hydroxy function, which allow formation of an 
amide or ester bond for the connection of the texaphyrin and 
nucleobase units. This bridge may also be modified, e.g., by 
the reduction of the amide bond to give the amine function. 
The present invention thus encompasses many possibilities 
for the connection of the same or different nucleobases to 
texaphyrin macrocycles. 
It is contemplated that expanded porphyrin-nucleobase 
conjugates will have a wide variety of applications, ranging 
from the use of texaphyrin-derived compounds as agents for 
selectively delivering an associated, biologically active 
nucleobase to a particular body, or even subcellular, locale 
to the more general use in laboratory protocols concerned 
with nucleotides or oligonucleotides. For example, in the 
case of antimetabolite nucleobases and texaphyrins, it is 
contemplated that the texaphyrin-nucleobase conjugates will 
act to deliver the antimetabolite to subcellular sites through 
intrinsic biolocalization, or through a covalently coupled 
site-directed molecule, such as an oligonucleotide, peptide, 
or hormone, for example. 
Expanded porphyrin-nucleobase constructs may employ 
only one nucleobase-containing substituent for each macro 
cycle; however, this is in no way a limitation upon the 
invention. For example, texaphyrin-nucleobase conjugates 
of the present invention may have any number of nucleo 
bases or nucleobase oligomers or polymers attached. The 
choice of base would be generally governed by the appli 
cation in which the conjugate was to be primarily used. 
Thus, it is contemplated that a texaphyrin-nucleobase con 
jugate with adenine will selectively bind thymidine, pre 
sumably through a hydrogen bonding of the two nucleotides. 
Furthermore, it is contemplated that polymers of texaphyrin 
nucleobase conjugates can be constructed and used to bind 
oligo- or poly-nucleotides through complementarity with the 
sequence of bases "encoded” on the texaphyrin-nucleobase 
polymer. 
The foregoing general structure could be exemplified by 
the formulas: 
X-X-X-X-X-X-X, etc. or X X X X X X, etc. 
N N N N N N N N-N-N-N-N-N 
Y-Y-Y-Y-Y-Y-Y Y-Yr-Y-Y-Y-Y 
wherein X is the texaphyrin macrocycle, N is the conjugated 
nucleobase structure, and Y is the hydrogen bonded poly- or 
oligonucleotide. 
Alternatively, it is contemplated that texaphyrins of the 
present invention may serve as a carrier for polymers of 
nucleobases, wherein the nucleobase polymers are attached 
covalently to the texaphyrin macrocycle, such as might be 
exemplified through the structural designation: 
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wherein X is a single texaphyrin macrocycle, and N is a 
selected oligomeric or polymeric nucleotide or other nucleo 
base, and Y is a hydrogen bonded poly- or oligonucleotide. 
Such structures would be useful in a number of contexts. 
In terms of texaphyrins, they are currently envisioned to be 
useful in RNA hydrolysis. In terms of sapphyrins, they may 
be used as specific carriers for taking complementary nucle 
otides into cells. The complementary nucleotides could be 
structures such as antisense molecules, including C-5 pro 
pyne-containing antisense oligonucleotides, designed to 
inhibit the transcription, translation or both, of a given gene 
or construct. Alternatively, they could be coding for "sense” 
strands of DNA which encode an entire gene, a functional 
protein domain, or any polypeptide, peptide, or fragment 
thereof. Such constructs may be used in in vitro molecular 
biological embodiments or in gene-transfer protocols in 
which the DNA is intended to act as a template for the 
production of proteins or peptides such as normally-func 
tional or therapeutically-important proteins and peptides. 
Chemically speaking, any number of nucleobase struc 
tures can be attached to a texaphyrin macrocycle. The 
ultimate number of such residues that are attached will, of 
course, depend upon the application. Where one intends to 
employ such a structure to purify complementary nucle 
otides, one may well desire to employ a structure having a 
polymer of at least 10 or so bases attached. However, for 
other applications, it may be convenient to design and 
employ texaphyrin-nucleobase constructs employing from 
one to three nucleobases per single macrocycle. Moreover, 
the nature of the intended use will dictate the number of 
attachment points there are on the texaphyrin macrocycle for 
attaching nucleobase moieties. Thus, while it may typically 
be the case that a single attachment site will suffice for most 
applications, for certain particular applications those of skill 
may find it particularly advantageous to attach various 
nucleobases at various of the subcomponents of the macro 
cycle. 
A. Purification Protocols 
There is currently a significant need for improved nucle 
otide- and oligonucleotide-binding compounds for use in 
connection with various laboratory techniques, both in clini 
cal and research embodiments. For example, oligonucle 
otides are currently purified using polyacrylamide gel elec 
trophoresis (PAGE) which is time-consuming, uses toxic 
materials, and is low-yielding. Ion exchange columns can, 
on a limited basis, sometimes separate oligonucleotides 
containing 40 or fewer residues. However, this process is 
also generally unsuitable as, for example, severe conditions 
such as elution at pH 2.7, are often required. The availability 
of a new column material, or improved functionalized glass 
capillaries, for use in chromatographically or electrophoreti 
cally separating nucleotides and oligonucleotides would 
thus represent a significant breakthrough in this area. 
The inventors' surprising discovery that expanded por 
phyrins, such as rubyrin, sapphyrin and texaphyrin, recog 
nize and bind phosphates, also lead the inventors to reason 
that such expanded porphyrins would be ideal for use in 
laboratory techniques to separate and purify nucleotides and 
oligonucleotides. This is a very important area to both 
scientists and clinicians as nucleotides, natural and synthetic 
oligonucleotides play critical roles in modern biotechnology. 
Oligonucleotides are used, for instance, as hybridization 
probes in blot analyses, primers for PCR amplification, and 
for sitespecific mutagenesis. Furthermore, in areas that are 
under FDA jurisdiction, oligonucleotide-derived products 













genetic diseases and for proviral HIV, the causative agent of 
Acquired Immunodeficiency Syndrome (AIDS)”. They are 
also being considered as potential chemotherapeutic agents, 
both directly, i.e., in gene therapy, and in an antisense 
fashion. 
All the above applications for using oligonucleotides 
require oligonucleotide materials of impeccable purity 
(often greater than >99.99%). Such purity, however, is not 
so easy to obtain using existing technology'. Presently, 
gene products and other oligonucleotide-type materials are 
purified using polyacrylamide gel electrophoresis (PAGE). 
This approach suffers from the drawbacks of being time 
consuming, requiring toxic materials, and is painfully man 
power-sensitive and low-yielding. 
Liquid chromatography, high performance liquid chroma 
tography (HPLC), and high performance affinity chroma 
tography (HPAC) using specialty silica gels are currently 
used to separate biological molecules. Indeed, silica gel 
phases with bonded groups, such as linear hydrocarbons, 
amino groups, cyano-groups, carboxylic amides and amino 
acids are all known. Unfortunately, few if any, of these 
phases are efficacious for the efficient, high-yielding sepa 
ration of nucleotides and oligonucleotides. 
Those that work best for this purpose are ion exchange 
columns which, on a limited basis, can Sometimes separate 
oligonucleotides containing 40 or fewer residues. However, 
this technique still suffers from several limitations, not least 
that it requires severe conditions, including elution at pH 
2.7, for routine operation. The use of high concentration 
buffers (greater than 1M), and gradients which often include 
formic acid or formamide, also limits the half lives of ion 
exchange columns. Furthermore, commercially available 
hydroxyapatite columns are limited for low pressure only 
(up to 719 psi). Reverse-phase columns are designed for 
pressures up to 5000 psi. However, this separative technique 
is based on hydrophobic interaction and, because there is not 
a specific interaction for phosphorylated species, it is not 
surprising that effective separation is not generally achieved. 
Recently, Takemoto et al. reported a new type of station 
ary phase in which purine and pyrimidine bases were 
bonded to the silica gel. With this support, base-pairing 
interactions between the nucleic acid base pairs and the 
modified silica gel were expected to improve resolution in 
nucleic acid separation. Although such stationary phases 
were used to separate nucleic acid free-bases, purine alka 
loids, nucleosides, and mono- and oligonucleotides, this 
approach unfortunately had least success with oligonucle 
otide separation, which is the most important area. Thus, 
there was still a critical need for improved solid-supports 
that would effectively separate nucleotides and oligonucle 
otides. 
The inventors realized that for a solid-support to be most 
useful in such embodiments, it must not only separate 
similar nucleotides and oligonucleotides from one another, it 
must do so rigorously and correctly based on chain length or 
size. Unfortunately, prior to the present invention, there were 
no suitable phosphate chelating agents that made this an 
achievable goal for use in either HPLC or electrophoretic 
Separation systems. 
B. Texaphyrin-Substituted Silica Gels and Merrifield Resins 
In certain embodiments, the matrix-supported expanded 
porphyrins of the present invention will be bonded, texa 
phyrin-substituted glass capillaries or silica gels that will 
serve as specific phosphate- or nitrate-chelating solid-Sup 
ports. These may be used in the chromatographic and 
electrophoretic separation of nitrates, phosphates and phos 
phorylated species, including nucleotides, oligonucleotides, 
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and DNA or RNA molecules including gene fragments, and 
will be suitable for both analytical and preparative HPLC 
applications. 
These aspects of the invention therefore encompass a full 
range of texaphyrin-modified stationary phases. When the 
bonded stationary phase or polymer is silica gel, the result 
ing products will be used for medium to high pressure 
applications. For low pressure applications, organic polymer 
based texaphyrins, for example, modified Merrifield resins, 
will be prepared using the same basic strategy. In all cases, 
the wide range of intrinsic variation, imparted via additional 
groups and the texaphyrin R groups will afford the oppor 
tunity to prepare stationary phases capable of separating a 
wide range of phosphorylated species. 
To date, a first generation texaphyrin-substituted silica gel 
has been prepared as described in Example 4. With this silica 
gel, a 3.2 mmx30mm HPLC column was packed (by Alltech 
Inc). Then, in the initial series of studies, this column was 
used to separate various, adenosine-derived nucleotide 
mono-, di-, and triphosphates with significant success. 
The ability to separate nucleotide mono-, di-, and triph 
osphates from cell extracts has long been a challenging task. 
Most of the commercially available HPLC columns provide 
less than adequate separation of di-from triphosphates. 
However, such separations are instrumental in determining 
cell energy charge (eq. 1), which is used as an indicator of 
cell health in the study of many diseases. 
ATP +0.5 (ADP) 
AMP + (ADP+ ATP 
A great advantage afforded by these aspects of the inven 
tion is that different numbers of texaphyrin molecules may 
be introduced per polymer unit simply by varying the molar 
ratio of texaphyrin derivative to the number of the groups 
bonded on the polymer surface. The inventors, therefore, 
also propose to vary the micromolar concentration of texa 
phyrin used per gram of silica gel in order to control the 
retention times and to influence peak shape characteristics. 
Straightforward modifications such as these will thus allow 
such systems to be used in both analytical and preparative 
modes. 
In addition to the separation of nucleotides, as described 
above, the inventors envision the separation of oligonucle 
otides using a matrix-supported metallotexaphyrin having 
little or no hydrolyric or cleavage activity towards oligori 
bonucleotides or oligodeoxyribonucleotides. Gadolinium is 
a preferred metal for this separation, however other metals 
such as lanthanum, lutetium, neodymium and yttrium are 
expected to be effective. 
Thus, it is clear that these new chromatographic supports 
are suitable for use in analyzing and purifying a large 
number of critical products, including small molecule anti 
viral agents and oligonucleotides such as hybridization 
probes and primers. They represent a marked advance over 
existing technology including PAGE, HPLC, HPAC, ion 
exchange columns and purine and pyrimidine base-bonded 
silica gels, and are expected to find many immediate appli 
cations in DNA-related biotechnology and medicine. 
Such matrix-supported texaphyrins are also contemplated 
for use in separating very large RNA or DNA molecules 
such as gene fragments and antisense constructs. In order to 
achieve separation of higher order oligonucleotides, the 
inventors envision that various elution-related parameters, 
such as, e.g., flow rate, buffer strength, and texaphyrin-to 
silica loading level, may be optimized so as to achieve the 
best possible separations. Second and/or third generation 
polymer-supported expanded porphyrins may also be pre 














pared for use in connection with RNA or DNA separation 
and purification. 
C. Second and Third Generation Texaphyrin Solid-Supports 
The preparation of improved, i.e., second and third gen 
eration, texaphyrin solid-supports is also contemplated. 
Such new systems will be designed to separate phosphory 
lated compounds based upon other specific binding modes in 
addition to the phosphate recognition provided by the moi 
ety. For example, hydrophobic interaction separation is 
contemplated, and can be provided by modifying the length 
of alkyl chains employed. Recognition mediated by Watson 
Crick hydrogen bonding interactions is also contemplated. 
This may be achieved by using expanded porphyrin-nucleo 
base conjugates, by appending nucleobases onto the solid 
support itself, or by using a combination of both methods. 
Introduction of aromatic ring (phenyl, substituted phenyl) or 
amino or silanol groups gives the possibility for TC-7t 
stacking interactions. 
The second generation stage of this new synthetic devel 
opment may be considered to be the stage of long chain alkyl 
addition. Long chain alkyl groups will thus be introduced 
onto the surface of the texaphyrin-substituted silica-gel. This 
will result in columns that will combine the properties of 
both reverse phase separation and texaphyrin-based phos 
phate chelation and ion exchange. Further, in light of the 
existing theories of HPLC, the inventors contemplate using 
appropriate synthetic modifications to optimize the retention 
characteristics of the columns so that they separate selec 
tively any desired length of oligonucleotide and/or gene 
fragment. 
The yet superior third-generation systems contemplated 
by the inventors are those in which the stationary phases will 
combine the best features of three different known modes of 
separation: hydrogen bonding, electrostatics, and reverse 
phase hydrophobicity. This will be achieved by using vari 
ous different substituents on both the texaphyrin molecules 
and on the stationary phase material itself. 
For example, in certain embodiments, these groups may 
be varied so as to introduce a nucleobase or nucleobase 
analog. Such nucleobase-bearing systems are expected to act 
in conjunction with the combined texaphyrin electrostatic 
and reverse phase hydrophobic interactions described above. 
Thus, by this triple combination, it is expected that the 
resultant solid phase will be able to separate nucleotides and 
oligonucleotides not only on the basis of charge and length 
but also on the basis of nucleic acid type. Such phases, of 
course, would prove to be of tremendous value in applica 
tions involving the analysis and purification of gene frag 
ments since these are often of similar size but of very 
different chemical (i.e., nucleic acid) composition. 
These same third generation phases would also be of 
tremendous benefit in the separation and analysis of AZT 
phosphate, dideoxycytidine phosphate, and other prodrugs 
used in the asymptomatic treatment of HIV and other viral 
infections. Here, in particular, it would be of significant 
value to have access to an analytical method that would 
allow one to distinguish the active phosphorylated nucle 
otide analogs from naturally occurring phosphorylated prod 
ucts, such as AMP or GMP, since this would allow for facile, 
on-line clinical analysis. 
D. Texaphyrin Substituted Capillary Electrophoresis 
In still further embodiments, the inventors also contem 
plate using polymer-supported texaphyrins in connection 
with capillary electrophoresis (CE). In CE, unlike HPLC, no 
solid silica or Merrifield resin support is used. Rather, 
differential adherence to the glass surface of a capillary is 
used to effect separation. Thus, in this embodiment, texa 
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phyrin-modified glass capillary surfaces will be prepared 
and used for improved CE resolution. In these embodiments, 
the polymer will be an untreated glass capillary rather than 
silica gel. Since glass is chemically similar to silica gel (both 
are silicate-derived), the preparation of a range of modified 
glass surfaces can be straightforwardly achieved in light of 
the present disclosure. 
Such texaphyrin-glass constructs may be used to separate 
natural and synthetic nucleotides and oligonucleotides. 
Here, as above, the best combination of complexed metals 
and substituent groups needed to effect any given type of 
separation will be determined. The information gained using 
silica gels will be applied in these considerations and 
Supplemented by further straightforward studies. It is 
expected that this will lead to a significantly improved new 
CE system. To highlight the utility of such a system, the 
inventors contemplate carrying out a Sanger sequencing of 
pBR322 using fluorescently labeled dideoxy nucleotides 
(Applied Biosystems Inc.). Since an entire range of fragment 
sizes is produced here, this will allow the superiority of the 
new texaphyrin-based approach to be quickly demonstrated. 
E. Polymer-supported Texaphyrins in Purification Protocols 
As described above and in the detailed examples, the 
inventors designed and constructed texaphyrin-based sup 
ports and used them to achieve-separation-of nucteotides, 
thus overcoming many of the existing drawbacks described 
above. Similar methods using a polymer-supported texaphy 
rin are envisioned to be of use purifying plasmid DNA, as 
described in Example 7D. 
Another technical area in which significant improvements 
could be made is in oligonucleotide analysis. For example, 
automated gene sequencing is currently carried out using 
either radio- or fluorescent-labeled nucleic acid gel electro 
phoresis. This technique is limited by the requirement for 
either slab or tubular polyacrylamide gels. An alternative 
approach, currently being considered on a research basis, is 
to use capillary electrophoresis. Unfortunately, this is lim 
ited when it comes to achieving separations based purely on 
electrostatics and oligomer size. Texaphyrins linked to glass 
capillary columns, as disclosed herein, provide new devices 
and methods that allow for such separation. This, therefore, 
represents a significant improvement in this area. 
A further utility of polymer-supported expanded porphy 
rins, i.e., texaphyrins and Sapphyrins is their use as tools in 
the removal of phosphate- or nitrate-containing environmen 
tal contaminants from ground water, soil, foodstuffs, and the 
like. The sapphyrins and texaphyrins have different binding 
mechanisms that may render one more useful in certain 
embodiments. For example, one may prefer to use a sap 
phyrin polymer-support to remove phosphates or nitrates 
from solutions. Metallotexaphyrins conjugated to solid 
supports offer a unique and distinct way of effecting the 
recognition and purification of anionic and neutral Sub 
strates. However, despite the different mechanisms, both 
texaphyrin and sapphyrin columns will likely bind and 
remove a variety of anionic compounds, with texaphyrins 
also binding to and being able to purify neutral molecules, 
such as sugars, including sugars present within the blood 
Streal. 
Texaphyrin and sapphyrin matrix-supports may be 
employed to analyze and separate pesticides such as Dichlo 
rovos, Phosphamidon, Diazanon, and Parathion, herbicides 
and fungicides, many of which contain organophosphorus 
compounds. Texaphyrin-substituted gels and columns may 
even be employed in the rapid detection and analysis of 
organophosphorus chemical warfare agents, allowing them 














Anionic species such as nitrates, phosphates and various 
metals elements are major sources of environmental pollu 
tion. In marine environments, an excess of nitrate can cause 
an imbalance of the water chemistry and lead to the forma 
tion of excess algae which can threaten the balance of the 
entire ecosystem. Similarly, excess nitrates in soil can lead 
to poor growth conditions for crops. Therefore, a system to 
remove excess nitrates, phosphates and metals from envi 
ronmental sources would be of great benefit for retaining the 
delicate balance in these ecosystems. 
F. Matrix-Supported Texaphyrins in Catalytic Schemes 
The ability to produce a wide range of matrices is depen 
dent on the ability to synthesize active catalysts. These 
catalysts must be able to convert the appropriate monomers, 
such as ethylene or styrene, to the desired polymeric mate 
rials. 
Lanthanide texaphyrin complexes have potential as active 
polymerization catalysts. There are several reasons for this. 
First, the texaphyrin ligand is essentially planar with the 
metal being slightly above the plane defined by the five 
chelating nitrogens, a geometry that allows access to the 
metal from either side of the macrocycle. Second, because 
the total coordination number of a metallotexaphyrin com 
plex is high while that of the ligand itself is low, the 
texaphyrin complexes should allow substrates such as alk 
enes or dihydrogen to be easily accommodated. Finally, the 
catalysts proposed herein will have two potential active 
sites. This is unlike any of the previous lanthanide based 
catalytic systems, which have been limited to cyclopenta 
dienyl type ligands and is important because, presumably, 
the catalytic cycle for either polymerization or hydrogena 
tion includes coordination of the substrate followed by a 
series of insertion steps. The cyclopentadienyl complexes by 
contrast are limited to one alkyl substituent being available 
for use in catalytic cycles, with this single alkyl being 
constrained in a crowded pocket. The texaphyrin complexes, 
on the other hand, will have two alkyl substituents in a, 
sterically speaking, rather open environment. Further, the 
macrocyclic ligand will disfavor formation of dimers which 
occur in the CMes based catalysts, which may enhance the 
rates of the catalytic reaction. 
The present invention now allows the lanthanide texa 
phyrin (txph) complexes, as linked to solid-supports, to be 
used as the basis for preparing a new set of potential 
polymerization and hydrogenation catalysts. These com 
pounds may now, for the first time, be employed in hetero 
geneous catalysis, as described below. 
As lanthanide coordinating ligands par excellence, the 
texaphyrins, when supported on solid matrices, provide a 
source of unparalleled Lewis acidity as a result, primarily, of 
the fact that trivalent cations of the lanthanide series are far 
better Lewis acids than cations of the more common metals. 
This Lewis acidity, in turn, allows for the use of texaphyrins, 
either free in solution or supported on supports, in a range 
of catalytic applications. These range from such standard 
catalytic applications of Lewis acidity as acyl transfer, ester 
hydrolysis, and amide hydrolysis to more sophisticated 
embodiments as phosphomono- and phosphodiester 
hydrolysis. 
In all cases, however, the critical catalytic step is thought 
to involve, in a mechanistic sense, the binding of a carbonyl 
or heteroatom-containing carbonyl-like oxygen lone pair to 
the coordinated texaphyrin metal center. This binding, in 
accord with the widely accepted principles of Lewis acid 
catalysis, will serve to activate the already acidic carbonyl 
carbon or heteroatom (e.g., phosphorus) for subsequent 
attack by a nucleophile. When this latter nucleophile is 
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provided by water, hydrolysis ensues; when it is provided by 
an alcohol, amine, or other standard nucleophilic organic 
group, acyl transfer results. Thus these catalytic systems, as 
normal for all catalysts (principle of microscopic reversibil 
ity) can be used to both make and break bonds. 
From a practical point of view, the general procedure will 
always be the same: Bring into contact with the solid 
supported Lewis acidic texaphyrin (e.g., polymer-supported 
Gd(III)texaphyrin), a particular desired substrate (ester, 
amide, phosphomonester, phosphodiester, etc.) in the pres 
ence of the chosen nucleophile (HO, ethanol, diethylamine, 
etc.). Reaction will then occur with all the advantages of 
normal heterogeneous catalysis (site isolation, easy product 
purification, facile catalyst recycling, etc.) resulting in a high 
yield of the desired product, be that one derived from 
hydrolysis or acyl transfer. 
The stability of the matrix-supported texaphyrin com 
plexes allows them to be subjected to harsh conditions, such 
as organic solvents and elevated temperatures, without 
breakdown of their structure. This property imparts a par 
ticular usefulness to the range of polymer-supported metal 
lotexaphyrins and, for example, allows them to be used as 
catalysts in various embodiments where the use of a bio 
logical catalyst, such as an enzyme, is impossible due to 
their instability and/or temperature sensitivity. 
On the other hand, Samarium (III) complexes are envi 
sioned to be particularly useful due to the relative ease of 
characterization compared to the remaining lanthanide com 
plexes. For instance, samarium complexes typically have 
narrow line widths in NMR spectra even though the metal 
center is paramagnetic. Therefore H and 'C NMR spectra 
may be used as standard characterization tools. In fact, this 
is the case for Sm(txph) (NO), which exhibits an "H NMR 
spectra resembling that of a diamagnetic complex. Con 
versely, the Gd(III) complexes with their known high relax 
ivity- inducing abilities will be useful for MRI applications. 
For both the Gd(III) and Sm(III) and other complexes, other 
characterization techniques will include IR, UV/vis, mass 
spectroscopy, elemental analysis and, when appropriate, 
single crystal X-ray diffraction analysis. Polymeric or oli 
gomeric materials obtained from these catalysts will be 
examined via standard polymer analyses including mass 
spectroscopy, GC/MS, gel permeation chromatography as 
well as those techniques listed above. 
When attached to a solid-support, particularly one of a 
biocompatible nature, these new paramagnetic materials will 
be of unique use as MRI-detectible catheters. These, in turn, 
will be of use for medical diagnosis applications. These, or 
similar, solid-supported materials will also be of use as 
heterogeneous Lewis acidic catalysts with the usual advan 
tages of site isolation, product purity, and catalyst recovery 
that would accrue from such heterogeneous catalysts. 
G. Matrix-Supported Texaphyrins in MRI 
Non-invasive techniques for the diagnosis of human dis 
ease are extremely valuable tools in the practice of modern 
medicine. One of the most important new techniques avail 
able uses magnetic resonance (MRI) to image tissues and 
organs within the body. This provides an advantage over the 
use of X-rays, which have harmful side-effects. A compli 
cation of this technique arises when the patient has a 
catheter, implant or other internal device which needs to be 
located within the body. At the present time, the majority of 
these devices are composed of materials that do not produce 
an adequate signal when subject to MRI. Therefore, cath 
eters and other devices composed of a material which is 















Gadolinium(III) complexes derived from strongly binding 
anionic ligands, such as DTPA and DOTA, are being devel 
oped for use in MRI. Indeed, GdDTPA) is undergoing 
clinical trials in the United States for possible use in 
enhanced tumor detection protocols. Nonetheless, the devel 
opment of other gadolinium(III) complexes with greater 
kinetic stability, superior relativity, and/or better biodistri 
bution properties was still a desirable goal until recent times. 
The provision of water-soluble texaphyrins for use in MRI 
enhancement, as described in U.S. Pat. No. 5,256,399, 
incorporated herein by reference, addressed this particular 
need. However, it did not provide a solution to the problem 
of locating a catheter or medical device using an MRI scan. 
This is an important application provided by the present 
inventors: that of using a metallotexaphyrin as a primary 
component of a catheter or device for enhanced visibility 
during MRI. This concept is more fully developed in 
Example 10. 
H. Matrix-Supported Texaphyrins in PDT 
Acquired immunodeficiency syndrome (AIDS) and can 
cer are among the most serious public health problems 
facing our nation today. AIDS is a fatal human disease that 
has now reached pandemic proportions. Cancer, in spite of 
some very significant advances in diagnostics and treatment 
in recent years, remains the third leading cause of death in 
this country. Finding better ways to detect, treat, and reduce 
the transmission of these disorders are thus research objec 
tives of the highest importance. 
One of the more promising new modalities currently 
being explored for use in the control and treatment of tumors 
is photodynamic therapy (PDT). This technique is based on 
the use of a photosensitizing dye, which localizes at, or near, 
the tumor site and, when irradiated in the presence of 
oxygen, serves to produce cytotoxic materials, such as 
singlet oxygen (O,(Ag), from otherwise benign precursors 
(e.g. (O,(X, )) Much of the current excitement associated 
with PDT derives from just this property: In marked contrast 
to current methods (e.g. conventional chemotherapy), in 
PDT the drugs themselves can (and should) be completely 
innocuous until "activated' with light by an attending phy 
sician. Thus, a level of control and selectivity may be 
attained which is not otherwise possible. 
Singlet oxygen is also believed to be the critical toxic 
species operative in experimental photosensitized blood 
purification procedures. This very new application of pho 
todynamic therapy is of tremendous potential importance: It 
shows promise of providing a safe and effective means of 
removing enveloped viruses such as HIV-1, herpes simplex 
(HSV), cytomegalovirus (CMV), various forms of hepatitis 
inducing virus, as well as other opportunistic blood-borne 
infections (e.g. bacteria and malaria plasmodium) from 
transfused whole blood. Given that AIDS is currently an 
ineffectively treated and usually fatal disease, the benefit of 
such a blood purification procedure would be of inestimable 
value. 
AIDS infections do still occur as a result of blood trans 
fusions. Unfortunately, banked blood components are essen 
tial products for the practice of modern medicine and as a 
result this method of transmission is not likely to be pre 
cluded by simple changes in lifestyle. Rather, a means to 
ensure that all stored blood samples are free of the AIDS 
virus (and ideally all other blood-borne pathogens) should 
be developed. To a certain extent, this can be accomplished 
by screening the donors' histories and carrying out serologic 
tests. At present, however, the serologic tests for HIV-1 are 
insufficient to detect all infected blood samples, in particular, 
those derived from donors who have contracted the disease 
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but not yet produced detectable antibodies. In addition, new 
mutants of the AIDS virus have been detected; some or all 
of which may escape detection by current means. Thus, an 
antiviral system is needed which removes any form of HIV-1 
from stored blood. This is particularly important since a 
stored blood sample from one infected donor could poten 
tially end up being administered to several different patients, 
in, for instance, the course of pediatric care. 
Texaphyrins and texaphyrin metal complexes are effective 
as photosensitizers for the generation of singlet oxygen. As 
described in U.S. Pat. No. 5,272,142, incorporated herein by 
reference, metallotexaphyrins can be used for the inactiva 
tion or destruction of tumors as well as for the prophylactic 
treatment and removal of human immunodeficiency virus 
(HIV-1), and other viral contaminants from blood. The 
metallotexaphyrins with CdCII), Sm(III), La(III), Lu(III) 
have been studied, and the CdCII) was found to be effective 
against certain types of leukemia cells. However, there are 
still many existing drawbacks to PDT. 
The present invention forms a basis for a novel treatment 
of diseases, such as leukemia, where the fluid from the body 
can be removed from the patient and exposed to PDT by use 
of a column which contains a polymeric supported texaphy 
rin. The treated fluid can then be reintroduced to the patient 
without fear of contamination from the texaphyrin. This 
avoids any unnecessary exposure of the patient's whole 
system to the effects of the photodynamic therapy. 
The matrix-supported texaphyrins of the present inven 
tion also allow for the deactivation of retroviruses and 
enveloped viruses in biological fluids, such as blood and 
blood products, using columns, filters or such like. These 
methods are advantageous as the fluids may be passed over 
the column. This may result in improved kinetics, but the 
very evident advantage is, again, that the treated fluid can be 
readily recovered and introduced to the patient without fear 
of contamination from the texaphyrin. 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
EXAMPLE 1. 
PREPARATION OF SAPPHYRIN POLYMERS 
For the preparation of certain polymers, sapphyrins with 
ethylene units could be used, as prepared by the elimination 
of acetoxy derivative, as well as sapphyrin bis acid, sap 
phyrin diamino and dihydroxyderivatives. Sapphyrins bear 
ing covalently attached nucleobases could also be used for 
the polymerization reactions. Example 10 of co-pending 
application, PCT publication WO 94/09003, is specifically 
incorporated herein by reference to supplement the present 
example. 
Radical polymerization may be catalyzed by dibenzoylp 
eroxide, or bisazaisobutyronitril in inert solvent attempera 
















tetramethylsapphyrin (1 mmol) and 1,1'-carbonyldiimida 
zole (1.1 mmol) were mixed in diphenylether for 1 hour, 
then 3,12,13,22-tetraethyl-8,17-diaminoethyl-2,7,18,23-tet 
ramethylsapphyrin (1 mmol) was added and reaction heated 
at 190°-250° C. for 2 hours. After cooling, dichloromethane 
was added, polymeric sapphyrin structure (where X-NH) 
was filtered off, washed with water (50 ml) and methanol (50 
ml). 
Polymeric sapphyrin was obtained also with using Sul 
folan, hexamethylphosphortriamide as a solvent. The reac 
tion could be also carried out without solvent. The same 
procedure was used for the sapphyrin dialcohol as a starting 
compound for the reaction with sapphyrin diacid. 
EXAMPLE 2 
SYNTHESIS OF POLYMER SUPPORTED 
SAPPHYRINS 
The new chromatographic bonded phases that are the 
subject of these aspects of the present invention were 
prepared in two steps. In the first, a phosphate thioether 
recognition unit was connected (via amide, ether, thioether, 
or NH bonds) with silica gel. This was followed, as a second 
step, by protection of residual silanol groups on the silica gel 
surface using a variety of silylating reagents (from C to 
Cs). The density of coverage for the covalently bonded 
recognition groups on the silica gel was controlled by the 
amount of expanded porphyrin, or guanidinium derivatives 
(in mmol) that was attached to 1 g of the starting silica gel. 
Elemental analysis data, namely comparison of the % C and 
% N in the starting material and the product, provided a 
measure of the ratio of phosphate receptor (in M) to 1 g of 
silica gel. Solid state 'P NMR spectra also provided a 
unique tool for the detailed study of the mechanism of 
phosphate binding. 
Example 11 of co-pending application, PCT publication 
WO 94/09003, is specifically incorporated herein by refer 
ence to supplement the present example. 
EXAMPLE 3 
GENERAL SILYLATION PROCEDURE 
For the separation of highly polar phosphorylated species 
on both analytical and preparative scale, the surface of silica 
gel must be modified by a silylation procedure. This proce 
dure basically converts most, if not all, the free silanol 
groups (-Si-OH) to -Si-O-Z type residues, where Z 
is an alkyl chain, or aryl substitution (ARCO-, ARCO-). 
Sillylation reagents which have been employed are those of 
type ZSiCl2, ZSiCl, and Z(CH)2SiCl, where Z is an alkyl 
residue with 1 to 18 carbon atoms in it or an ary (phenyl, 
pentafluorophenyl) substituent. 
For the silylation of the bonded silica gels in this inven 
tion, the present inventors have used the following proce 
dure: Introduction of the C, C, C2, and C groups by 
reaction of mono and trichlorosilanes with suspended 
bonded silica gel in an organic solvent (dry dichlo 
romethane, dichloroethane, benzene, toluene, Xylene, or 
pyridine and 2.6-lutidine was used directly as a solvent) 
either directly or in the presence of organic bases such as 
pyridine or 2.6-lutidine, in a temperature range of 25 
C-150° C. for the preparative HPLC phases, the corre 
sponding triflates were used for silylation. 
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Example 12 of co-pending application, PCT publication 
WO 94/09003, is specifically incorporated herein by refer 
ence to supplement the present example. 
EXAMPLE 4 
SYNTHESIS OF TEXAPHYREN-BONDED 
SILICA 
The synthesis of texaphyrin-bonded silica gel was accom 
plished by amide bond formation between activated (Eu) 
texaphyrin carboxylic acid (carbodiimide method) and 
amino-substituted silica gel. 
A. Synthesis of (Eu) Texaphyrin Acid EuT2B1 
(O(CH2)CO2H) 
The sp texaphyrin derivative T2B1.HCl, (having 
O(CH2)COH as an R substituent on the B portion of the 
molecule, 0.694g, 1 mmol, see U.S. Pat. No. 5,252,720 for 
T2B1 structure) was dissolved in 80 ml of dry methanol. Eu 
(OAc).HO (0.329 g, 1 mmol) was added, followed by 
triethylamine (0.5 ml). The reaction mixture was heated at 
reflux with the reflux condenser open to the air for 6 hours, 
with the progress of metallation being followed by visible 
spectroscopy. The methanol solvent was evaporated off 
under reduced pressure to give a dry, dark solid that was 
washed with dichloromethane for 2 hours under conditions 
of vigorous stirring. 
The product was filtered off, redissolved in MeOH (25 
ml), and the solution was treated with zeolite (a procedure 
for removing free europium salt). The product 4a was then 
twice precipitated from methanol by adding diethylether. 
The resulting dark green solid was then collected and dried 
under high vacuum overnight. The yield was 91.0%. 
Characterization data: Elemental analysis for 
CHNOEu. 2(OAc) (F.W. 920.855) calc. 54.78% C, 
5.47% H, 7.61% N; found 54.46% C, 5.50% H, 7.55% N. 
FAB HRMS: For CHNOEu calc. 802.24626; found 
802.247752. UV-Vis (EtOH, max): 420,469,760 nm. 
B. Procedure for the Synthesis of Texaphyrin-Bonded Silica 
Gel 
(Eu)-texaphyrin carboxylic acid 4a (M=Eu, R=CHOH, 
n=3, 0.50 mg) was dissolved in a mixture of dichlo 
romethanedimethylformamide (1:1,5 ml) and cooled to 0° 
C. The carbodiimide derivative was then added (EDC, 100 
mg), followed by 1-hydroxybenzotriazole. The resulting 
reaction mixture was kept for 45 minutes at this temperature 
and slowly added to the 3-aminopropyl silica gel (1 g of 
3-aminopropyl silica gel, Sigma Company, 1.0 mmol N per 
gram), suspended in dry dichloromethane (25 ml) containing 
0.5 ml of dry pyridine. The reaction mixture was stirred at 
0°C for 30 minutes and then at room temperature for 3 days. 
The product was filtered off, washed with dichloromethane 
(30 ml), methanol (50 ml), water (100 ml), methanol (50 
ml), and dichloromethane (30 ml). The product 4b was dried 
(giving 1.035 g) and used for further derivatization, namely 
direct silylation, or 1) introduction of other functional 














4b. M = trivalent metals such as Y(III), In(III), Ln(III), where 
Ln = Lanthanide; H2N-R represents an amino-functionalized 
solid support 
C. Sillylation procedure 
(Eu) texaphyrin-silica gel as described above (1.0 g) was 
suspended in dry dichloromethane (30 ml) containing dry 
pyridine (3 ml). To this solution, a solution of dimethyldi 
chlorosilane (2 ml) in dry dichloromethane (10 ml) was then 
slowly added before the resulting reaction mixture was 
allowed to stir for days at 30° C. The product was isolated 
by filtration and washed as described above. The yield was 
1.04 g. 
Also used in the silylation procedure was trimethylsi 





described in co-pending application, PCT publication WO 
94/09003, specifically incorporated herein by reference for 
the purposes of describing further silylation procedures. 
EXAMPLE 5 
SECOND AND THIRD GENERATION 
TEXAPHYRIN SOLD-SUPPORTS 
The preparation of improved second and third generation 
texaphyrin Solid-Supports may be achieved in many ways. 
For example, in one stage of the synthetic development, long 
chain alkyls may be introduced onto the surface of the 
texaphyrin-substituted silica-gel. This is contemplated to 
result in second-generation columns that will combine the 
properties of both reverse phase separation and ion 
eXchange. 
Examples 15 and 16 of co-pending application, PCT 
publication WO 94/09003, are specifically incorporated 
herein by reference for the purposes of supplementing the 
present example in terms of the preparation of second and 
third generation matrix-supported texaphyrins. 
Improved, third generation texaphyrin solid-supports may 
also be prepared. For example, third-generation systems 
may be prepared in which various different substituents on 
both the expanded porphyrin molecules and on the station 
ary phase material itself are chosen to impart the desired 
groups and properties to the resultant material. 
In one case, nucleobase-bearing systems may be gener 
ated which are expected to be able to separate nucleotides 
and oligonucleotides not only on the basis of charge and 
length but also on the basis of nucleic acid type. The use of 
nucleobase-bearing systems to hydrolyse RNA oligonucle 
otides with sequence specificity is also contemplated. The 
introduction of aryl substituents give the possibility for 
improved separation based on phosphate chelation and TL-TL 
stacking. Any substituent for multiple type separation may 
be introduced by acylation, akylmethylation on free amino 
groups and/or by silylation with phenyl (substituted phenyl), 
silyl reagents or arylmethylation of OH groups. 
More specifically, the following text describes the prepa 
ration of partially texaphyrin-functionalized 3-aminopropyl 
silica gel suitable for the introduction of additional func 
tions. This sorbent was prepared for the second and third 
generation of columns, with the intention to leave a certain 
number of amino groups free (unbound to texaphyrin) for 
the subsequent binding of other types of recognition units. 
The latter functional groups include both hydrogen-bond 
recognition units for nucleobases, aromatic residues capable 
of effecting T-7t stacking interactions with the pyrimidine 
or purine rings of nucleotides, as well as, in certain embodi 
ments, other expanded porphyrins such as texaphyrins and 
Sapphyrins. 
Also, for phosphodiester hydrolytic purposes an imida 
zole ring can be easily introduced by reaction with amino 
protected (e.g. 1-BOC-L-Histidine). A positive charge near 
the texaphyrin macrocycle can also be introduced by reac 
tion with, for example, L-arginine methylester. 
EXAMPLE 6 
SEPARATION OF NEGATIVELY CHARGED 
SPECIES USENGATEXAPHYRIN 
SOLID-SUPPORT COLUMN 
The present example sets forth various procedures that are 
contemplated to be of use in connection with the polymer 













of co-pending application, PCT publication WO 94/09003, 
is specifically incorporated herein by reference for the 
purposes of supplementing the present example in terms of 
the separation of negatively-charged species using expanded 
porphyrin matrix-supports. 
Columns using the new bonded texaphyrin materials are 
stable in aqueous buffers from pH 4.0 to pH 9.0, with 
operation at pH 5.0 being preferred in certain embodiments. 
They are also stable to normal organic solvents and the 
packings are mechanically rigid due to their silica gel 
backbone. Indeed, the chemical and mechanical stability of 
such new columns makes them suitable for use over long 
periods of time without loss of resolution. Moreover, col 
umns made from the presently described supports do not 
compress at high pressure and flow rates. The use of surface 
modified spherical silica gels results in products for use in 
medium to high pressure applications. For low pressure 
applications, organic polymer based solid-supports, for 
example, modified Merrifield resins, may be used. 
It is contemplated that the effectiveness of separation 
using these new stationary phases will be far superior to 
those currently used. Also, the lifetimes of the columns are 
long because only very mild elution conditions are required: 
low concentration of buffer at neutral pH. Usually, isocratic 
(i.e., non gradient) conditions are sufficient for the separa 
tion even for very complicated mixtures. This makes the 
analysis of a series very fast and there is no need for column 
equilibrium after each analysis. 
These advantageous features allow for the rapid and 
efficient separation of nitrates, phosphates and different 
phosphorylated species, such as nucleotides, mono-, di- and 
triphosphates, oligonucleotides, DNA and RNA fragments, 
phosphosugars, phosphoproteins and organophosphorus 
compounds, using the expanded porphyrin-based solid-Sup 
ports of this invention. 
Texaphyrin columns are prepared using a standard col 
umn packing procedure. In this context, the columns are 
slurry-packed in methanol or acetone, followed by a wash 
with water. An HPLC pump that generates a solvent flow of 
about 10 ml/min at 300-400 bar is used. 
A. Separation of mono-, di-, and tri-phosphorylated nucle 
otides using a Sapphyrin solid-support 
Using the first generation of the sapphyrin-substituted 
silica gel the inventors were able to successfully separate 
adenosine and its mono-, di-, and tri-phosphorylated nucle 
otide forms. 
The results of the HPLC separation of adenosine, mono-, 
di-, and tri-phosphates using the first sapphyrin-modified 
silica gel were very striking. Commercially obtained 
adenosine, AMP, ADP, and ATP were prepared by dissolving 
in 5 mM tris (hydroxymethyl)aminomethane buffer at pH 
7.0. An adenosine, AMP, ADP, and ATP mixture, (201), was 
loaded onto and eluted off the sapphyrin-modified silica gel 
using an isocratic buffer of 100 mM dibasic ammonium 
phosphate buffer at a pH of 7.0 and a flow rate of 0.2 ml/min 
(or, in another study, 500 mM buffer and a flow rate of 1.0 
ml/min). The wavelength of 260 nm was monitored and 
results were confirmed with retention times and UV-visible 
spectrum obtained from samples of individual compounds. 
It is clear that there is a striking difference between the 
sharp peaks using the new sapphyrin-based technology and 
the unresolved broad band obtained with a more conven 
tional column. 
B. Separation of Mono-, Di-, and Polyanionic Species Using 
a Metallotexaphyrin Solid-Support 
The present inventors have demonstrated that silica 
bound lanthanide texaphyrins, specifically, europium(III) 
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texaphyrin can effectively separate mono-, di-, and polyan 
ionic species under isocratic HPLC conditions. 
Two separate studies were performed to determine 
whether the silica-bound europium texaphyrin would be 
specific to different anions. HPLC columns were packed 
with the silica-bound europium texaphyrin of Example 4 by 
Alltech, Inc. (Deerfield, Ill.) at the request of the inventors 
and according to standard column packing procedures. Ben 
zoic acid, benzene sulfonic acid, diphenylphosphate, and 
phenylphosphate were injected into a 3.2 mm (i.d.)x30mm 
HPLC column. The mobile phase used was 50/50 (v/v) 
methanol/10mM sodium acetate, 20 ml, (pH=7). The results 
are given in Table 3. 
TABLE 3 
Substrate Time (min.) 
Benzoic Acid 5.9 
Benzene Sulfonic Acid 6.0 
Diphenyl Phosphate 6. 
Phenyl Phosphate 16.8 
As Table 3 shows, the type of anion is less relevant than the 
charge of the anion. Phenyl phosphate at a pH of 7 is a 
dianionic species, while benzoic acid, benzene sulfonic acid, 
and diphenyl phosphate are monoanionic. 
To confirm this result, 5'-adenosine mono-, di-, and triph 
osphate as well as 3',5' cyclic adenosine monophosphate 
were injected onto the HPLC column. The results are 
summarized in Table 4. 
TABLE 4 
Substrate Time (min.) 
Adenosine 1.2 





As shown in Table 4, the monoanionic cyclic AMP eluted at 
nearly the same time as the neutral adenosine. The other 
phosphate derivatives showed a much higher affinity for the 
solid phase than the monoanionic cyclic AMP. 
There was no indication that the dinucleotide, ApA, had 
come off the column even after 8h. As a control, the same 
solution was tested on a commercial 3.2 mm (i.d.)x100mm 
reverse phase column. ApA was eluted after 30 minutes 
using a similar flow rate and buffer as used with the 
"texaphyrin column.” Eutexaphyrin can hydrolyze phos 
phodiesters in solution (U.S. Ser. No. 08/227,370, incorpo 
rated by reference herein), and it is expected that the ApA 
was hydrolyzed by the EuTXP. 
The present data show that the expanded porphyrin, 
texaphyrin, when metallated with a lanthanide metal, was 
able to effectively separate adenosine, AMP, ADP and ATP. 
Since crystal structures of dysprosium texaphyrin show that 
phosphate anions ligate to the dysprosium via axial binding, 
the inventors believe that the separation is via axial ligand 
binding to the lanthanide metal in the texaphyrin macro 
cycle. Varying the metal in the macrocycle is expected to 
achieve varying degrees of selectivity between anions. 
When a higher order nucleotide, ApA, was used, the 
silica-bound texaphyrin hydrolyzed the phosphodiester bond 
between the nucleotides. Varying the metals in the solid 
support bound texaphyrin macrocycle will vary the rate of 
hydrolysis and the specificity of hydrolysis. 















Using the first generation sapphyrin substituted silica 
gels, the inventors were able to successfully separate 2-, 3-, 
4-, 5-, 6-, 7-, 8- and 9-mer oligonucleotides. 
Results of the HPLC separation of commercially obtained 
adenosine-derived oligonucleotides using the first sapphy 
rinmodified silica gel were significant. Samples of 2-, 3-, 4 
and 5-mers of polydeoxyadenylic acid were prepared by 
dissolving in 5 mM of tris (hydroxymethyl)aminomethane at . 
pH 7.0. This mixture (20 pul) was loaded onto and eluted off 
the column using an isocratic buffer of 100 mM dibasic 
ammonium phosphate at pH 7.0 and a flow of 0.35 ml/min. 
The wavelength of 260 nm was monitored and results were 
confirmed with retention times and UV-visible spectrum 
obtained from samples of individual compounds. 
The results obtained with the sapphyrin-based methodol 
ogy were very impressive. There was a marked difference 
between the sharp, distinct peaks observed and the broad, 
unresolved peak obtained when the same mixture was run 
through a control column with no sapphyrin. Furthermore, in 
addition to separating out the oligonucleotides in this sup 
posedly pure mixture, higher and lower order impurities 
were also observed. 
Results of the HPLC separation of longer commercially 
obtained adenosine-derived oligonucleotides using the first 
sapphyrin-modified silica gel were also impressive. A 
sample of a mixture of 2-, 3-, 4-, 5-, 6-, 7-, 8- and 9-mers of 
polydeoxyadenylic acid was loaded onto and eluted off the 
column using 100 mM dibasic ammonium phosphate at pH 
7.0 and a flow of 0.35 ml/min. The wavelength of 260 nm 
was monitored and results were confirmed with retention 
times and U/V-visible spectrum obtained from samples of 
individual compounds. 
These results are also striking, and effective separation of 
all species was achieved. Clearly, all of these results are 
remarkable, particularly as various impurities, not known to 
be present in the commercially available mixture, were 
identified, the presence of which was later confirmed at 
source (Sigma Chemical Co.). 
D. Separation of Nitrates 
The binding of nitrates is contemplated to be of signifi 
cance in removing nitrates from water samples, including, 
for example, drinking water, particularly for babies, and also 
water in fish tanks and aquariums-there is currently no way 
of achieving this. Of course, removal of both nitrates and 
phosphates, such as alkylphosphonates and detergents, from 
contaminants of waste water or ground water is also con 
templated. 
EXAMPLE 7 
MATRIX-SUPPORTED TEXAPHRYINS FOR 
USE IN PURIFICATION PROTOCOLS 
The present example details further embodiments in 
which the matrix-supported texaphyrin compositions are 
contemplated to be particularly useful. 
A. Purification of Anionic Species 
Metallotexaphyrins conjugated to solid-supports offer a 
unique new way of effecting the recognition and purification 
of anionic substrates. This is because they possess, coordi 
nated within their central cores, large metal cations that 
necessarily (by definition) are Lewis acidic and hence able 
to bind, as apical or axial ligands various Lewis basic 
entities, including those that are negatively charged. How 
ever, the degree of this Lewis acid-to-Lewis base interaction 
is a function not only of the particular metal center coordi 
nated to the central, pentaazatexaphyrin core, but also of the 
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Lewis base itself, since the latter could vary in the degree of 
basicity or ligand donor strength as well as in size and steric 
accessibility. Thus, when allowed to interact in a chromato 
graphic sense with a given texaphyrin, maintained on a 
solid-support, individual Lewis basic materials will be 
retained differentially. 
Texaphyrins linked to solid-supports therefore provide 
highly selective means for separating species from solutions 
of different anionic materials. When a solution is contacted 
with the texaphyrin-based solid-support and subjected to 
standard elution procedures, distinct components will be 
released at different rates. They can then be collected as 
small eluent fractions to allow for the obtainment of the 
various components of the original anion mixture in a 
partially or completely purified fashion. 
Here, it is readily apparent that this purification method 
ology would be equally applicable to thin layer chromatog 
raphy (TLC), high pressure liquid chromatography (HPLC), 
batch separations (where bulk washings rather than constant 
elutions are used), and electrophoretic applications; in all 
cases it is the now disclosed substrate-to-texaphyrin inter 
actions, rather than the specifics of the chromatographic 
separation, that are considered to be key. 
B. Purification of Neutral Species 
Metallotexaphyrins, as is apparent from inspection of 
numerous crystal structures'', also bind neutral entities as 
apical ligands provided that these entities are electron rich 
(i.e., Lewis basic). Thus, texaphyrins conjugated to solid 
supports can also be used to effect the chromatographic or 
electrophoretic separation of neutral, Lewis basic entities. 
Here, as above, it is the fact that different neutral substrates 
differ in their ligation ability (because of differences in 
Lewis basicity, sterics, etc.) that makes such separations 
possible. Specifically, modulations in interactions (with the 
texaphyrin metal centers) will correlate with differences in 
retention and/or elution behavior such that one desired 
substrate can be separated out from a mixture of similar, but 
still different, substrates and hence obtained in purified form. 
C. Purification of Oligonucleotides and Related Materials 
The separative purification of oligonucleotide and other 
polyphosphorylated substrates represents a specific embodi 
ment of the above Lewis base-to-texaphyrin based proce 
dure. Here, however, the major advantage that the presently 
disclosed approach would provide over the currently avail 
able methods is an ability to separate ostensibly similar 
materials on the basis of total phosphate number. This is 
because oligonucleotides, for instance, of different length 
would present to the texaphyrin-bearing surface a number of 
total interactive axial ligands that differ absolutely. Thus, the 
degree of interaction between the texaphyrin surface and the 
substrate in question, i.e., an oligonucleotide of different 
length. As a consequence, the order of elution would be 
different in a chromatographic or electrophoretic sense and 
a means for differential purification established. 
D. Purification of Plasmid DNA 
An important application of lanthanide(III) texaphyrin 
(LnTx) functionalized polymers involves their utility in the 
separation of plasmid DNA from RNA, protein, and other 
cellular contaminants. Current protocols describe proce 
dures for lysis of bacterial cells and provide a source of 
crude plasmid DNA (e.g., Sambrook, Fritsch, and Maniatis, 
Molecular Cloning, 2nd Edition, Cold Spring Harbor Labo 
ratory Press, 1989, 1.21-1.39) which is then further puri 
fied either by treatment with pancreatic RNase and precipi 
tation with polyethylene glycol (cf. Sambrook, 1.40-1.41) or 
by equilibration centrifugation in cesium chloride-ethidium 














former procedure is inappropriate for larger (>15 kb) DNA 
plasmids (cf. note in Sambrook 1.37) while the latter pro 
cedure is labor and time consuming and employs the toxic 
chemical ethidium bromide. 
The use of matrix-supported texaphyrins presents a novel 
alternative method of purification, whereby unwanted RNA 
contaminants are removed by virtue of their susceptibility to 
hydrolysis by the lanthanide complexes. Treatment with the 
solid-supported LnTx catalyst therefore results in the deg 
radation of RNA to mononucleotides, which are readily 
removed using a standard ethanol precipitation. Unwanted 
protein is also readily removed by virtue of its relatively low 
affinity for the solid-supported LnTx. An example of a 
typical purification protocol is described immediately below. 
The crude nucleic acid pellet, obtained by the boiling, 
SDS, or alkaline lysis methods (Sambrook, 1.34-1.39), is 
resuspended in 3 mL of Tris EDTA buffer, pH 8.0. An 
appropriate amount of, e.g., silica bead supported LnTX is 
added to this solution, the suspension vortexed, and incu 
bated in a heat block at greater than 37 C. for a period of 
time sufficient to effect complete hydrolysis of the RNA. The 
suspension is then cooled, washed into an eppendorf pipette 
tip to form a small column using Tris-EDTA buffer, and 
washed briefly to remove remaining protein. The purified 
DNA is then eluted from the solid-supported LnTx using a 
sodium phosphate buffer. The resulting DNA is precipitated 
using one-tenth volume of 3M sodium acetate, pH 5.4 and 
three volumes of ethanol. The supernatant is decanted, the 
DNA pellet washed with 70% ethanol, and allowed to 
air-dry. The purified DNA is resuspended in any desired 
buffer. 
EXAMPLE 8 
MATRIX-SUPPORTED TEXAPHYRINS FOR 
USE IN CATALYSIS 
The present example sets forth various ways in which 
matrix-supported metallotexaphyrins may be employed to 
catalyze a variety of chemical transformations. 
A. Catalysis of Phosphodiester Hydrolysis 
Solid-supported lanthanide texaphyrins provide a unique 
means of catalyzing the hydrolysis of phosphodiesters. The 
Lewis-acidic lanthanide metals coordinated within the texa 
phyrin bind the phosphate, thus activating the phosphate 
towards hydrolytic cleavage. Thus, a suspension of the 
solid-supported lanthanide texaphyrin can be treated with a 
solution of a phosphodiester (such as RNA) resulting in the 
hydrolysis of the phosphodiester. The catalysts may then be 
easily removed by a simple filtration. Thus, products may be 
easily separated from the catalysts. 
An alternative method would be to develop continuous 
flow processes. In such a process, the phosphodiester solu 
tion is passed over a stationary catalyst bed. The phosphodi 
ester interacts with the texaphyrin complexes resulting in 
hydrolysis of the diester. Product is then collected as the 
solution exits the catalyst bed. 
These applications are also pertinent to the hydrolysis of 
phosphomonoesters. Thus, using the procedures described 
above the phosphate group of a phosphomonoester may be 
completely removed. These processes are of particular inter 
est when applied to site-selective RNA hydrolysis. 
The fact that europium texaphyrin attached to a solid 
support can catalytically hydrolyze phosphodiester bonds at 
neutral pH was demonstrated in Example 4. Therefore, 
two-phase catalytic hydrolysis of phosphodiesters is pos 
sible. The inventors envision using silica bound texaphyrin 
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for phosphodiester hydrolysis of polynucleotides (DNA or 
RNA) by injecting them onto a column or stirring them in a 
round bottom flask, and extracting the hydrolyzed nucle 
otides. Gadolinium- and dysprosium-texaphyrin have both 
been shown to hydrolyze phosphodiester bonds by the 
present inventors. 
B. Catalysis of Polymerization 
A stirred suspension of solid-supported lanthanide texa 
phyrin alkyl complexes may be treated with an appropriate 
monomer solution (ethylene, styrene, acetylene, pheny 
lacetylene, etc.) resulting in polymer formation. Additional 
monomers (different from the initial monomer) may be 
added to this solution resulting in a block polymer. After 
complete polymerization has occurred the catalyst may be 
removed by filtration resulting in a purified polymer suitable 
for a variety of applications including household plastics or 
machine parts. 
C. Catalysis of Hydrogenation 
A hydrogen-saturated solution of alkene will be stirred 
with a suspension of the solid-supported lanthanide texa 
phyrin hydride complexes under a hydrogen atmosphere. 
The alkene will be hydrogenated to the corresponding 
alkane. The catalyst may then be removed by a simple 
filtration step resulting in a purified alkane suitable as a feed 
stock for the petroleum and chemical industries. 
EXAMPLE 9 
MATRIX-SUPPORTED TEXAPHYRINS FOR 
RACEMATE RESOLUTION 
The present example describes the use of matrix-sup 
ported texaphyrins as chiral sorbents for HPLC. By the 
introduction of a chiral unit into the texaphyrin periphery, a 
sorbent for racemate resolution can be generated. Specific 
examples of chiral groups are D-glucopyranosyl, glu 
cosamine, L-amino acids, such as L-alanine, or L-phenyla 
lanine residues, oligopeptides, oligosaccharides and chiral 
binaphthyl systems. 
The resultant chiral matrix-supported texaphyrins could 
be used for D.L-aminoacid separation, as well as for the 
separation of chiral phosphates, such as synthetic nucleotide 
monophosphates with modified ribose units, phospholipids, 
phosphoproteins, phosphorylated saccharides, and the like. 
These same polymer-supported texaphyrin chiral sorbents 
may be also used to effect catalytically a range of enan 
tiotopic reactions, from chiral phosphate ester hydrolysis to 
stereoselective polymer genesis. 
The following describes two general procedures for the 
coupling of carboxy-substituted chiral texaphyrins with an 
amino-functionalized solid-supportin DMF or a water-DMF 
mixture. 
A. Using 1,1'-Carbonyldiimidazole as a Coupling Reagent 
1 mol. eq. of carboxylated texaphyrin was dissolved in 
dry DMF, 1.1 moleq of 1,1'-carbonyldiimidazole was added 
and stirred under argon for 4 hours. Then the amino 
component (1 mol eq.) was dissolved in a water-pyridine 
mixture (10:0), or in a buffer of pH 8.5 or higher (this is 
needed for successful coupling), and slowly added to the 
solution of activated carboxy-component. The reaction mix 
ture was stirred at room temperature for 1-5 days or at 37 
C. for 24 hours. During this period, the reaction could be 
followed by HPLC analysis. The work up includes evapo 














B. Using Carbodiimide as a Coupling Reagent 
Texaphyrin acid (1 mole. eq.) was dissolved in dry DMF 
and the solution cooled to 0° C. for 1 hour. The reaction 
mixture was then stirred at room temperature for 2-5 days, 
with the course of the reaction being followed by HPLC. The 
product was isolated by filtration and washing. 
EXAMPLE 10 
MATRIX-SUPPORTED TEXAPHYRINS FOR 
USE IN MRI 
This example sets forth various ways in which matrix 
supported metallotexaphyrins may be used in medical 
devices, such as catheters, to enhance visibility during 
magnetic resonance imaging. 
As disclosed in U.S. Pat. No. 5,252,720, incorporated 
herein by reference, nonlabile Gd(III) complexes of 
hydroxy-substituted texaphyrins are useful contrast agents 
for MRI applications. Rats bearing subcutaneously 
implanted methylcholanthrene-induced fibrosarcomas in 
their left flanks (n=4) have been studied for imaging pur 
poses, where results showed that the T2B2 gadolinium 
texaphyrin complex is a hepatic, renal and tumor-specific 
contrast agent. The agent was found to have relatively low 
toxicity in rodents. Tumor enhancement persisted for up to 
28 hours. After this initial showing of utility in MRI, the 
inventors have developed the concept of using polymer 
supported texaphyrins in other aspects of MRI, as set forth 
below. 
In connection with the present example, U.S. Pat. No. 
5,256,399 is also specifically incorporated herein by refer 
ence for the purposes of supplementing the present example 
where it concerns the use of texaphyrins in methods for MRI 
enhancement and in methods for detecting neoplastic tis 
SLCS. 
The ability to image internal body structures and diseased 
tissues non-invasively within a patient's body has become 
indispensable to the practice of modern medicine. A variety 
of such non-invasive imaging techniques exist, including 
X-ray imaging, ultrasonic imaging, X-ray computed tomog 
raphy, emission tomography, and the like. 
MRI can provide two-dimensional sectional images 
through a patient, providing color or gray scale contrast 
images of soft tissue, particularly for imaging tumors, 
edema, infarcts, infections, and the like. In addition to high 
quality, magnetic resonance images are particularly desir 
able since they do not expose the patient to harmful radia 
tion. 
However, patients undergoing magnetic resonance imag 
ing often have catheters, tubes, implants, and other devices 
present within their bodies, and the precise anatomical 
locations of such devices can be of substantial clinical 
importance. Unfortunately, most catheters and many other 
devices are composed of materials, such as organic poly 
mers, which do not produce adequate signals for detection 
by magnetic resonance imaging techniques. In particular, 
most polymeric catheters are not clearly discernible on 
magnetic resonance images unless they are surrounded by 
tissue that has a high signal intensity, in which case they 
leave a dark void on the image. 
It is therefore highly desirable to provide catheters and 
other medical devices that have enhanced detectability when 
viewed using MRI regardless of the nature of the surround 
ing tissue. Here, it is contemplated that a texaphyrin com 
plexed to an imaging ligand, such as Gd(III), and then linked 
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to a catheter or device would be of great use in providing a 
high contrast image when viewed under MRI. Texaphyrins 
may be linked to catheters and devices by the same basic 
synthetic methodology that is employed, and described 
herein, to link texaphyrins to any other polymeric matrix. 
The ions used for MRI may be any metalion that displays 
paramagnetic properties and that binds to a texaphyrin, with 
exemplary transition metal cations including Gd(III), Cu(II), 
Ni(II), Co(III), Co(II), Fe(III), and Fe(II), with Gd(III) being 
preferred. 
The polymeric materials particularly suitable for use in 
such catheters and devices include, for example, polyethyl 
ene, polyurethane, polyvinyl chloride, nylon, latex, silicone 
rubber, halogenated polyethylenes (e.g., polytetrafluoroeth 
ylene (PTFE) and other Teflon(E) materials), organosilicones 
(e.g., Silastic(R) materials) and biocompatible ceramics. 
After linking the metallotexaphyrin to the polymeric 
material, the combination would then be formed into a tube, 
or shaped device, by conventional techniques, such as, e.g., 
injection molding or extrusion at elevated temperatures. 
Suitable extruders utilize polymeric materials and, by apply 
ing heat and pressure, form the materials to a continuous 
length of tubing having a desired diameter and wall thick 
ness. The metallotexaphyrins of this invention may be 
incorporated throughout such tubes uniformly, or may be 
located only in a portion of the tube, such as a distal portion, 
or in a plurality of circumferential bands, e.g., axially spaced 
apart along the tube. Provision of such lengths and/or bands 
of paramagnetic ions can be achieved by periodically intro 
ducing the paramagnetic-texaphyrin complex into the poly 
meric material. As a further alternative, the paramagnetic 
ions can be provided along an axial line or strip of the 
flexible tubing, e.g. by introducing the texaphyrins into the 
extruder at one circumferential region of the tube as it is 
extruded. 
These aspects of the invention are contemplated to be 
useful for modifying conventional catheters, feeding tubes, 
drainage tubes, shunts and other medical or veterinary 
devices that have component tubes. It is also suitable for use 
in generating improved interventional devices, such as those 
used for suturing and/or biopsy, and all devices that may be 
temporarily introduced into an animal's or patient's body, 
lumen or tissue. Texaphyrins may also be used to modify 
portions or components of permanently implantable devices, 
Such as joint and other prostheses, breast implants, pace 
makers, drug injection ports, pediatric intercardiac devices 
and even drug delivery devices, where it is desirable that the 
presence and location of the device be readily discernible 
during subsequent magnetic imaging procedures. 
EXAMPLE 11 
MATRIX-SUPPORTED TEXAPHYRINSAS 
INTERNAL RADIOACTIVE SOURCES 
This example sets forth various ways in which matrix 
supported metallotexaphyrins may be used in medical 
devices, including the types of catheters described immedi 
ately above, as part of radioimmunodiagnostics (RID) and 
radiosensitization therapy (RIT) protocols. It should be 
cautioned that all known uses of radioligands are not without 
their drawbacks and side-effects, and the same is true for the 
polymer-supported texaphyrins described herein. 
Radioisotopes play a central role in the detection and 
treatment of neoplastic disorders. The more stable, polymer 














employed in radiosensitization and therapy (RIT), where the 
radiometal of interest must be bound and retained under 
physiological conditions. The potential damage arising from 
"free” radioisotopes, released from the complex, can be very 
serious. The advantage of a chelate, and particularly, a 
polymer-supported texaphyrin metal complex, that does not 
allow for metal release is clear. 
For the purposes of imaging, an ideal isotope should be 
readily detectable by available monitoring techniques and 
induce a minimal radiation-based toxic response. In practice, 
these and other necessary requirements implicate the use of 
a Y-ray emitter in the 100 to 250 KeV range, that possesses 
a short effective half-life (biological and/or nuclear), decays 
to stable products, and, of course, is readily available under 
clinical conditions. To date, therefore, most attention has 
focused on 'I(t=193 h), ''I(t=13 h), ''"Tc(t=6.0 
h), ''Ga(t=78 h) '''In?t=67.4 h) which come closest to 
meeting these criteria. 
Texaphyrin forms a kinetically and hydrolytically stable 
complex with In(III); such a ligand system may be elabo 
rated and serve as the critical core of a matrix-supported 
texaphyrin conjugate for use in 'In-based radioimmuno 
diagnostics. Although not proposed for immediate clinical 
use, it is expected that a matrix-supported texaphyrin, e.g., 
a highly directable, small catheter, could be employed to 
deliver a radiotherapeutic insult to the center of a solid tumor 
that is not readily targeted by agents present in the blood. 
Texaphyrins having electron donating groups on the 2, 7, 12, 
15, 18 and/or 21 positions of the present invention are 
particularly suited for this application due to their enhanced 
stability. A texaphyrin complexed to 'Y may be adminis 
tered in combination with another texaphyrin complexed to 
a diamagnetic metal for photodynamic tumor therapy, for 
example, to achieve a synergistic killing of malignant cells. 
EXAMPLE 2 
MATRIX-SUPPORTED TEXAPHYRINS FOR 
USE IN PHOTODYNAMIC THERAPY 
This example sets forth the uses of matrix-supported 
metallotexaphyrins in photodynamic therapy (PDT), as may 
be used, for example, to kill certain types of leukemia cells 
and to inactivate viruses. 
A. Viral Inactivation by Matrix-Supported Texaphyrins 
One example of the utility of the present invention is the 
use of matrix-supported texaphyrins for photon-induced 
deactivation of viruses and virally-infected or potentially 
infected eucaryotic cells. U.S. Pat. No. 5,252,720, incorpo 
rated herein by reference, teaches that unsupported texaphy 
rins may be used to inactivate peripheral mononuclear cells 
and enveloped viruses. The columns of this invention are 
contemplated for use in inactivating viruses such as Herpes 
Simplex Virus Type 1 (HSV-1), HIV-1, HIV-2, FIV, SIV, and 
the like. 
Texaphyrins having electron donating substituents in the 
2, 7, 12, 15, 18 and/or 21 positions of the macrocycle, as 
shown in structure I and described in PCT application 
PCT/US95/01996, incorporated herein by reference, are 
expected to be more effective photosensitizers for the 
destruction of free enveloped viruses such as HIV-1, virally 
infected peripheral mononuclear cells, as well as leukemia 
and lymphoma cells. 
The novel treatment methods made possible by the 
matrix-supported texaphyrin technology include those in 
which fluid from the body is removed from the patient and 
exposed to PDT by use of a column which contains a 
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matrix-supported texaphyrin. The treated fluid may be re 
introduced into the patient. 
The matrix-supported texaphyrins may also be used to 
remove functional viruses, such as HSV and HIV, from 
biological fluids, such as blood and plasma, or used as an 
additional control measure to ensure that blood samples do 
not contain viruses before storage or transfusions. 
B. Photodynamic Therapy for Tumors 
U.S. Pat. No. 5,252,720, incorporated herein by reference, 
demonstrates that La(III)B2T2 texaphyrin is phototoxic to 
murine mammary carcinoma cells in vitro and to murine 
adenocarcinoma tumor masses in Balb/c mice in vivo. 
Improved, novel treatment methods made possible by the 
present matrix-supported texaphyrin invention include those 
in which fluid from a cancer patient is removed and exposed 
to PDT using a column that contains a polymer-supported 
texaphyrin. The treated fluid will then be re-introduced into 
the patient. This is particularly suitable for purging tumor 
cells from the blood of patients with leukemia. 
EXAMPLE 13 
TEXAPHYRIN SUBSTITUTED GLASS 
CAPILLARIES 
Matrix-supported expanded porphyrins may be prepared 
in which the matrix is a glass capillary, for example, as may 
be used in capillary electrophoresis (CE). As glass is chemi 
cally similar to silica gel (both are silicate-derived), the 
preparation of modified glass surfaces may be achieved 
generally as described herein. The preparation of texaphyrin 
modified 3-amidosubstituted glass and texaphyrin modified 
arylamine glass would be essentially as described in 
Example 17 of co-pending application, PCTWO 94/09003, 
that is specifically incorporated herein by reference for the 
purposes of supplementing the present example in terms of 
the preparation of second and third generation matrix 
supported texaphyrins. 
EXAMPLE 14 
SYNTHESIS AND INTERACTIONS OF 
TEXAPHYRIN-OLIGONUCLEOTIDES 
PCT publication WO94/29316 is incorporated by refer 
ence herein for methods relating to texaphyrin-metal-com 
plex-mediated ester hydrolysis. U.S. Ser. No. 08/310,501 is 
incorporated by reference herein for methods relating to 
texaphyrin mediated photocleavage of a polymer of DNA. 
A. Metallotexaphyrins with Amine, Thiol or Hydroxy 
Linked Oligonucleotides 
Amides, ethers and thioethers are representative of link 
ages that may be used for coupling oligonucleotides to 
texaphyrin metal complexes. Oligonucleotides functional 
ized with amines at the 5'-end, the 3'-end, or internally at 
sugar or base residues, are modified post-synthetically with 
an activated carboxylic ester derivative of the texaphyrin 
complex. Alternatively, oligonucleotide analogues contain 
ing one or more thiophosphate or thiol groups are selectively 
alkylated at the sulfur atom(s) with an alkylhalide derivative 
of the texaphyrin complex. Oligodeoxynucleotide-complex 
conjugates are designed so as to provide optimal catalytic 
interaction between the RNA or DNA phosphoester back 
bone and the matrix-supported texaphyrin-bound lanthanide 
cation(s). 
Oligonucleotides are used to bind selectively compounds 
which include the complementary nucleotide or oligo or 













sequences. As used herein, a substantially complementary 
sequence is one in which the nucleotides generally base-pair 
with the complementary nucleotide and in which there are 
very few base pair mismatches. The oligonucleotide will 
generally be large enough to bind probably at least 9 
nucleotides of complementary nucleic acid. A general 
method for preparing oligonucleotides of various lengths 
and sequences is described by Caracciolo et al. (1989)'. 
In general, there are two commonly used solid phase 
based approaches to the synthesis of oligonucleotides con 
taining conventional 5'-3' linkages, one involving interme 
diate phosphoramidites and the other involving intermediate 
phosphonate linkages. In the phosphoramidite synthesis a 
suitably protected nucleotide having a cyanoethylphospho 
ramidate at the position to coupled is reacted with the free 
hydroxyl of a growing nucleotide chain derivatized to a 
solid-support. The reaction yields a cyanoethylphosphite, 
which linkage must be oxidized to the cyanoethylphosphate 
at each intermediate step, since the reduced form is unstable 
to acid. 
The phosphonate based synthesis is conducted by the 
reaction of a suitably protected nucleotide containing a 
phosphonate moiety at a position to be coupled with a solid 
phase-derivatized nucleotide chain having a free hydroxyl 
group, in the presence of a suitable activator to obtain a 
phosphonate ester linkage, which is stable to acid. Thus, the 
oxidation to the phosphate or thiophosphate can be con 
ducted at any point during synthesis of the oligonucleotide 
or after synthesis of the oligonucleotide is complete. 
The phosphonates can also be converted to phosphora 
midate derivatives by reaction with a primary or secondary 
amine in the presence of carbon tetrachloride. To indicate the 
two approaches generically, the incoming nucleotide is 
regarded as having an "activated” phosphite/phosphate 
group. In addition to employing commonly used solid phase 
synthesis techniques, oligonucleotides may also be synthe 
sized using solution phase methods such as triester synthe 
sis. The methods are workable, but in general, less efficient 
for oligonucleotides of any substantial length. 
Preferred oligonucleotides resistant to in vivo hydrolysis 
may contain a phosphorothioate substitution at each base. 
Oligodeoxynucleotides or their phosphorothioate analogues 
may be synthesized using an Applied Biosystem 380B DNA 
synthesizer (Applied Biosystems, Inc., Foster City, Calif.). 
B. Hydrolysis of Monoesters by Lanthanide (III) T2B2 
Texaphyrin 
This section provides an example of the utility of the 
present invention in the hydrolysis of monoesters, in par 
ticular, the hydrolysis of UpU, cuMP, 3'-UMP and 2'-UMP. 
Described are results from studies using the lanthanide (III) 
T2B2 texaphyrin (U.S. Pat. No. 5,252,720, incorporated by 
reference herein). Using the synthetic methodology of the 
present invention, a matrix-supported lanthanide (III) T2B2 
texaphyrin would be constructed and used as described 
hereinbelow for the unsupported complex. It is contem 
plated that the matrix-supported version would function 
essentially as the free version, but would provide the many 
additional advantages associated with being attached to a 
column. 
Cytosine, uridine, uridine-2' and 3'-monophosphate diso 
dium salt (2'-UMP and 3'-UMP), uridine-2',3'-cyclicmono 
phosphate sodium salt (cUMP), and uridylyl(3'-5') uridine 
ammonium salt (UpU) were purchased from Sigma (St. 
Louis, Mo.) and used without further purification. All solu 
tions, unless otherwise stated, were prepared from a stock 
solution of 5.0 mM N-(2-hydroxyethyl) piperazine-N'- 
ethanesulfonic acid (HEPES), in Milli-Q purified water, 
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adjusted to pH 7.0. Solutions were stored and reactions 
conducted in RNAse free plastic vials further sterilized by 
heating at 120° C. for 20 minutes in an autoclave. All kinetic 
runs were thermostated at 37 C. in a water bath. 
High-performance liquid chromatography (HPLC) was 
performed on a Waters 501 equipped with a Waters model 
440 absorbance detector, monitoring at 254 nm. A YMC, 
Inc., USA ODS-AO column (150 mmX4.6 mm I.D.) was 
used. Satisfactory separation was achieved with an isocratic 
gradient (10 mM NaH2PO adjusted to pH 5.6 with 1% 
methanol) with a flow rate of 1.0 ml/min. A Beckman DU-7 
spectrometer was used to confirm the concentrations of 
EuB2T2 txp. 
Eu(NO). In the control, the reaction solutions were 
prepared by diluting 100 ul of UpU (2.94 mM), 25 ul of 
Eu(NO) (3.5 um), and 100 ul of cytosine (0.423 mM), as 
internal standard, in 375 ul of 5.0 mM HEPES solution. The 
reactions were carried out as for EuB2T2 txp. The pseudo 
Zero order rate constant for the control reaction was deter 
mined to be k=(2.2+0.8)x10 mM/h. 
EuB2T2 txp. In a typical kinetics analysis, the reaction 
solutions were prepared by diluting 100 ul of UpU (2.94 
mM), 50l of EuB2T2 txp (7.8 mM), and 100 ul of cytosine 
(0.423 mM), as internal standard, in 350 ul of 5.0 mM 
HEPES solution. The rate of UpU hydrolysis was monitored 
by removing 15 ul aliquots which were frozen until HPLC 
analysis was possible. All samples were microfiltered (0.2 
um) prior to injection on the HPLC. All runs were performed 
in triplicate. The background as determined from the simul 
taneous control containing no metal complex was negligible. 
The pseudo-Zero order rate constant for the reaction was 
determined to be k=(9.1+1.6)x10 mM/h at 37° C., pH 7.0. 
The pseudo-Zero order rate constant for the hydrolytic 
cleavage of a ribodinucleotide by the nitrate salt of the water 
soluble EuB2T2 texaphyrin has been examined. Investiga 
tions indicate that a 0.15 mM aqueous solution of Eu(B2T2 
txph)” hydrolytically cleaved uridylyl (3'-5') uridine, 
UpU, (0.49 mM) with a pseudo-Zero order rate of (9.1+1.6)x 
10 mM/h at 37° C., pH 7.0. In the absence of the metal 
complex no evidence of RNA cleavage was observed by 
HPLC. The reaction was followed by HPLC, monitoring the 
formation of uridine. Uridine-2-monophosphate, uridine-3'- 
monophosphate, and uridine-2':3'-cyclicmonophosphate 
(cuMP) were also observed by HPLC; this indicates a 
hydrolytic rather than an oxidative mechanism for the cleav 
age reaction. Uridine-2':3'-cyclicmonophosphate reached a 
steady state concentration, implying that the texaphyrin 
complex hydrolyzed cUMP as well. Under identical condi 
tions, a 0.15 mM aqueous solution of Eu(NO) has a 
pseudo-zero order rate constant of 2.2+0.35)x10 mM/h. 
Therefore, small traces of free metal ions cannot account for 
the hydrolysis observed in the presence of the texaphyrin 
metal complex. Under these conditions, the Eu(III) complex 
of HAM displayed a pseudo-zero order rate constant of 
4.1x10 mM/h. Thus, the texaphyrin complex is found to be 
more effective than the HAM system. 
A survey of other lanthanide (III) complexes of the B2T2 
texaphyrin indicates that these complexes are also capable of 
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1.16 x 10 
4.69 x 10 
6.3 x 10 
499 x 10 
144 x 10 
6.0 x 10 
4.16 x 10 
1.9 x 10 
The concentrations of the Lanthanide (III) B2T2 txph (NO) are all approxi 
mately 0.25 mM. 
Further evidence supporting the catalytic effect of the 
texaphyrin metal complex was obtained by monitoring the 
formation of uridine produced from the Eu(T2B2Txp)(EI) 
catalyzed decomposition of uridine-2',3'-cyclicmonophos 
phate (cUMP). The decomposition of cQMP (0.10 mM) 
catalyzed by Eu(T2B2Txp)(II) (0.15 mM), when incubated 
at 37° C. and pH-7.0 (5 mM HEPES buffer), had a pseudo 
zero order rate of 6.94x10 mMh' for the production of 
uridine. Examination of the reaction products by HPLC 
indicated that initially, cUMP is isomerized to uridine-3'- 
monophosphate (3'-UMP) and uridine-2-monophosphate 
(2'-UMP) which are subsequently hydrolytically cleaved to 
produce uridine. 
C. Generalized Hydrolysis of RNA Using a Texaphyrin 
Metal Complex 
This section describes the use of europium texaphyrin in 
degrading a population of RNA molecules. P'-labelled 
RNA transcripts from an isolated clone was the homogenous 
RNA substrate. The transcripts and their degradation prod 
ucts were visualized by polyacrylamide gel electrophoresis 
and autoradiography. Using the synthetic methodology of 
this invention, a polymer-supported europium texaphyrin 
would be created and used as described hereinbelow for the 
unsupported complex. It is contemplated that the polymer 
supported version would function essentially as the free 
version, but with the significant added advantages associated 
with being attached to a column, e.g., the purification of the 
hydrolysed products. 
pGEMG)-3Z vector and Riboprobe® RNA transcript sys 
tems were obtained from Promega Corporation, Madison, 
Wis. A 4.3 kb fragment of the mouse 1b Multi Drug 
Resistant gene (MDR) was cloned into the EcoRI site of the 
pGem 37 vector and its orientation determined. The plasmid 
was used in transcription reactions and when digested with 
BamHI, T7 RNA polymerase makes a transcript from this 
template that is approximately 2000 bases long. The tran 
scription reaction consisted of 100 ng of BamHI digested 
pGem 37/4.3 MDRH3, 20 ul of 5x transcription buffer, 
triphosphate nucleotides (A,C,G) at 500 uM, UTP at 100 
uM, 50 uC of '-Po-UTP (3000 Ci/mmol), 10 mmol DTT, 
120 units of RNasin and 70-100 units T7 RNA polymerase. 
This reaction was brought up to a total volume of 100 ul with 
DEPC treated double distilled water. The reaction was 
allowed to incubate at 37° C. for 1.5 hours. The entire 
reaction volume was then run over a G-50 Sephadex column 
(Nick column, Pharmacia) pre-equilibrated with 20 mM Tris 
pH 7.0, 2 mM EDTA, 0.1% SDS. The transcript was eluted 
from the column in the second 400 il volume applied to the 
column. Any unincorporated nucleotide was left on the 
column. 
Ten ul aliquots of the transcript were put into separate 
tubes and stock solutions of Eu(III)txp, EDTA or Eu(III) 
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acetate were added so that the final volume was 20 ul. The 
tubes were allowed to incubate for 2 hr at 37° C. Thirty ul 
of dye mix (formamide, 0.2% bromphenol blue) was added 
to each tube. The tubes were mixed and heated at 60° C., 5 
min, then the entire content of the reaction was loaded Onto 
a 5% 8M urea polyacrylamide gel and electrophoresis was 
performed. 
The results of the digests of the 2000 base long transcripts 
with EuB2T2 txp showed that there is one band in the 
control and control with EDTA. This band was absent in the 
lane with 100 M EuB2T2 txp. An increase in lower 
molecular weight material, i.e. degradation products, was 
seen as smearing throughout. The transcript remains intact at 
the lower EuB2T2 txp concentrations. The transcript is 
degraded with 100 uM EuB2T2 txp in the presence of 500, 
300, 100 and 10 uM amounts of EDTA. This study elimi 
nates the possibility that free metal in the B2T2 txp solution 
is causing the degradation. The 100, 50, 25, 10 and 5 uM 
concentrations of free Europium metal salt (EuOAc) did not 
digest the transcript. These results are not affected by the 
presence of EDTA. 
A digestion of total RNA (primarily 28s and 18s riboso 
mal RNA from K562 cells) with EuOAc, EuT2B2 txpand 
GdT2B2 txp indicated that all are able to hydrolyze total 
RNA. The digestions were performed in 50% DMSO and 
H2O, the gel was electrophoresed using a 10 uM phosphate 
buffer, pH 6.8. It is likely that EuOAc digests the homoge 
neous transcript also but at higher EuOAc concentrations 
than those used in the present example. 
Clearly, EuB2T2 texaphyrin is able to hydrolyze RNA 
substrates. Since the texaphyrins have such versatility for 
functionalization, this result has significant implications for 
the construction of site-specific cleaving reagents for nucleic 
acids. 
D. Site-Specific Hydrolysis of RNA by Europium(III)-Texa 
phyrin Conjugated to a Synthetic Oligodeoxyribonucleotide 
The present section provides antisense agents using a 
texaphyrin metal complex-oligonucleotide conjugate that 
effects the hydrolysis of its RNA complement without the 
participation of endogenous nucleases. A DNA-EuTx-oligo 
nucleotide conjugate was synthesized based on the function 
alized texaphyrin. This "ribozyme analogue' provides an 
example of oligodeoxynucleotide-directed, metal catalyzed 
hydrolysis of a complementary RNA oligomer. Polymer 
supported DNA-EuTx-oligonucleotide conjugates, created 
as described above, could be used as described for the 
unsupported complex. It is contemplated that the polymer 
supported version would function essentially as the free 
version, but with all the advantages associated with being 
attached to a column, such as the purification of the hydroly 
sed products. 
Two 20-mer oligonucleotides were machine-synthesized 
to contain alkylamine groups at either the 5-position of an 
internal thymine residue or the 5'-end terminal phosphate. 
Oligodeoxynucleotide-amines modified on the 5-position of 
thymine were purchased from Oligo's Etc. (Wilsonville, 
Oreg.); oligodeoxynucleotide-amines modified on the 5' end 
were purchased from Keystone Laboratories, Inc. (Menlo 
Park, Calif.). Oligonucleotides were HPLC purified and 
precipitated using LiCl prior to use. Reaction of the car 
boxylic acid functionalized europium(III) texaphyrin com 
plex (8 of U.S. Ser. No. 08/227,370) with carbodiimide and 
N-hydroxysuccinimide produced the corresponding acti 
vated ester, which was added directly to a solution of the 
chosen oligodeoxynucleotide amine. The resulting DNA 
EuTx conjugates were purified by electrophoresis. 
A synthetic RNA 30-mer was obtained as substrate (Key 













selected from a unique site within the gene transcript for 
multiple drug resistance. Sequence is complementary at 
1562 bases post-transcriptional start site in mouse multidrug 
resistance protein mRNA. The 3'-'P-labelled substrate was 
incubated with an excess of oligodeoxynucleotide conjugate 
at 37° C. for 18-24 h in a buffered salt solution, ethanol 
precipitated, and assayed on a 20% denaturing polyacryla 
mide gel. About 30% cleavage occurred near the expected 
location of the europium (III) texaphyrin complex upon 
hybridization with the conjugate. Cleavage yield was mea 
sured by densitometry and calculated as ratio of cleavage 
band to intact material. The corresponding cleavage bands 
were not observed when this same substrate was incubated 
with oligonucleotides that were non-complementary in 
sequence, unmodified, or were modified internally with the 
complex. Control reactions indicate that ambient light, calf 
thymus DNA or type of buffer (Tris acetate or HEPES, 
EDTA, pH 6.0-8.0) had no apparent effect on cleavage 
efficiency. EDTA inhibits cleavage by free lanthanide (III) 
cations. 
The cleavage fragments co-migrate with bands in 
sequencing lanes produced by incubation of substrate under 
alkaline conditions or subjected to partial digestion with a 
series of base-specific ribonucleases. This observation is 
consistent with a hydrolytic mechanism, presumably involv 
ing the EuTx acting as a Lewis acid that facilitates an 
intramolecular attack of the 2'-hydroxyl group to effect 
cleavage. There are bands indicating site-specific cleavage 
of the ribonucleotide target sequence in the absence of any 
added cleavage reagents. Although the source of this back 
ground cleavage is unknown, it is believed to be the direct 
result of a higher order structure (i.e., a hairpin) of the 
oligoribonucleotide, since hybridization with any comple 
mentary oligonucleotide dramatically inhibits the cleavage. 
This type of structure-dependent cleavage behavior has been 
seen previously with oligoribonucleotides. 
Maximal cleavage activity of the Eu(III)Txp-oligonucle 
otide was observed down to 25 nM conjugate. Decreased 
cleavage below this level may be due to a decrease in 
hybridized material (as judged by increased background 
cleavage of the target RNA present at a concentration of 
about 1 nM). By means of comparison, the free europium 
complex non-specifically hydrolyzed the RNA substrate at 
25uM. In the control reaction containing both complex and 
the non-derivatized complementary DNA oligomer, cleav 
age occurred predominantly in the single stranded region, 
although still at lower efficiency than the Eu-Tx-DNA 
conjugate at 2.5 nM. Thus, attachment of the EuTx to the 
DNA probe increases its effective concentration ca. 10,000 
fold. A target RNA without the secondary structure observed 
here would likely allow for cleavage at lower DNA-EuTx 
concentrations. These data indicate the utility of such con 
jugates in specific cleavage applications. 
As demonstrated in the present example, the selectivity of 
the texaphyrin complexes is enhanced by covalently linking 
oligonucleotides onto the periphery of the macrocycle. Since 
the metal complexes do cleave RNA over DNA preferen 
tially, the DNA appendages would remain intact during the 
hydrolysis. The DNA arm will recognize and bind to an 
appropriate RNA segment, effectively increasing the metal 
concentration at these loci relative to the overall metal 
concentration in solution. Phosphate ester hydrolysis will 
therefore be significantly increased at specific locations 
along the RNA backbone. In one embodiment, primers 
(known or deduced) for PCR could be coupled to a hydro 
lytic divalent or trivalent texaphyrin complex to induce 
hydrolysis of proximal RNA or DNA. 
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Matrix-supported texaphyrin complexes that bind to 
complementary RNA or DNA sequences via an appended 
oligonucleotide could be employed to cleave RNA or DNA 
proximal to this specific site. Either one or two texaphyrin 
molecules may be attached to the DNA. 
In light of the present disclosure, one skilled in the art will 
readily recognize that solid-supported catalysts can also be 
developed from the homogeneous hydrolysis catalysts 
described in each of the sections B through D. The advan 
tages of the new solid-supported catalysts will include ease 
of separation of catalyst from substrate and product as well 
as the development of continuous flow processes. 
E. Site-Specific Light-Dependent Cleavage of DNA by 
LuTxp-Oligonucleotide Conjugate 
The present section provides for the site-specific light 
dependent cleavage of DNA by lutetium(III) texaphyrinoli 
gonucleotide conjugate. 
A reaction mixture was prepared by adding ca. 300,000 
cpm of 5'-'P-labeled DNA 36-mer (4 uL) to a solution made 
from lutetium(III) texaphyrin-oligonucleotide conjugate 
(2.5 L, 407 nM stock solution, Rs of the texaphyrin was 
NH-(CH2)-PO- oligonucleotide), 4x buffer (5 ul) 
and water (8.5 pull) to produce a final volume of 20 ul. The 
oligonucleotide portion of the conjugate was complemen 
tary to a region of the DNA 36-mer. Final conjugate con 
centration was 50 nM. The 4x buffer is 400 mM. NaCl, 200 
mM HEPES, pH 7.5, 100 uM EDTA. Eight reaction mix 
tures were pipetted into O-ring type Eppendorf tubes (1.6 
mL). Two additional reaction mixtures (tubes 1 and 6) were 
prepared in the same way, except that an equal volume of 
water was substituted for the LuTx-DNA conjugate. Tubes 
1-5 were covered with an atmosphere of oxygen, and tubes 
6-10 with an atmosphere of argon. Samples were sealed 
with parafilm, vortexed and centrifuged briefly, and then 
irradiated with laser light via the side of the Eppendorf tube. 
The laser was set at 752 nm and a power density of ca. 150 
mW/cm' was used (ca.20% reduction of laser power density 
is estimated to occur due to attenuation by the Eppendorf 
tube). Samples were irradiated for 1, 5, 10, or 30 minutes, 
whereupon the DNA was precipitated with ethanol using 
standard methods. The samples were resuspended in 50% 
formamide loading buffer, denatured at 90° C. for 5 minutes, 
and analyzed by electrophoresis on a 20% denaturing poly 
acrylamide gel. 
Control reactions containing free lutetium(III) B2T2 texa 
phyrin were prepared by adding ca. 300,000 cpm of 5'-'P- 
lableled DNA 36-mer (4 uL) to a solution made from 
lutetium(III) texaphyrin B2T2 (U.S. Pat. No. 5,252,720, 
incorporated by reference herein) (5 II, 2 uM stock solu 
tion), 4x buffer (5 ul) and water (6 ul) to produce a final 
volume of 20 L. Final LuB2T2Tx complex concentration 
was 500 nM. Eight reaction mixtures were pipetted into 
O-ring type Eppendorf tubes (1.6 mL). Two additional 
reaction mixtures (tubes 11 and 16) were prepared in the 
same way, except that an equal volume of water was 
Substituted for the LuB2T2Tx solution. Tubes 11-15 were 
covered with an atmosphere of oxygen, and tubes 16-20 
with an atmosphere of argon. Samples were irradiated, 
ethanol precipitated, and analyzed by electrophoresis as 
described above. 
The resulting autoradiograph indicated substantial cleav 
age only in those lanes that contained the 12-mer LuTx 
DNA conjugate. The cleavage sites covered four residues, 
proximal to the anticipated location of the LuTx-DNA 
conjugate. Both the locations of cleavage and the much 
greater efficiency of conjugate cleavage relative to that 














hybridization of the DNA increases the local concentration 
of the LuTx and effects site-specific cleavage. 
The autoradiograph also contained information regarding 
cleavage mechanism: The presence of oxygen in reactions 
2-5 clearly increased the efficiency of DNA strand breakage. 
That cleavage occurred at all in samples under argon is 
presumably attributable either to ambient light prior to the 
layering with argon, or else to incomplete replacement of the 
atmosphere in these tubes. The positive effect of oxygen on 
cleavage implicates singlet oxygen or other oxygen product 
as the intermediary species responsible for DNA strand 
breakage. 
The maximal extent for cleavage observed was roughly 
5% and was obtained after 5 minutes of laser irradiation. It 
is possible that the actual yield of reaction is far greater, 
since the initial step in cleavage is likely a nicking step and 
complete cleavage would be facilitated, for example, in 
vitro, by an organic base such as piperidine. Not wanting to 
be bound by theory, it is possible that singlet oxygen attacks 
a purine base, adenine for example, and causes depurination 
of double-stranded DNA similar to the Maxam and Gilbert 
chemical cleavage of DNA. 
Further irradiation had no effect on the amount of cleav 
age. This observation is consistent with self-destruction of 
the 12-mer LuTx conjugate (which is also composed of 
DNA) or may reflect an instability of the LuTx complex 
towards laser light. The disappearance of low mobility 
material assigned as non-denatured DNA-LuTx conjugate 
duplex at greater laser irradiation times provides additional 
support for these possibilities. 
F. Sequence-Specific Light-Dependent Cleavage of DNA by 
LuTxp Conjugated to 2'-O-Methyl RNA 
The present section provides for the site-specific light 
dependent cleavage of DNA by lutetium(III) texaphyrin-2'- 
O-methyl RNA oligonucleotide conjugates. 
Reaction mixtures were prepared by adding ca. 100,000 
cpm of two different 5'-'P-labeled DNA 36-mers (A, B) to 
solutions made from lutetium(III) texaphyrin oligonucle 
otide conjugate (O-Me oligonucleotide complementary to 
portion of A) (1.0 ul, 968 nM stock solution) or Lu(III) 
Txp-oligonucleotide conjugate (O-Me oligonucleotide 
complementary to portion of B) (3.0 uL, 335 nM stock 
solution), 4x buffer (5 L) and water to produce a final 
volume of 20 uL. Final conjugate concentration was 50 nM. 
The 4x buffer is 400 mM NaCl, 200 mM HEPES, pH 7.5, 
100 M EDTA. Two conjugate-free controls (samples 1 and 
8) were prepared by substituting water for conjugate solu 
tion. Samples 1, 4-8, and 11-14 were irradiated for 4.5 
hours at 37° C. using a 75 watt incandescent light at ca. 9 
inches above the heating block. Samples 2, 3,9, and 10 were 
incubated without exposure to light at 37°C. The DNA was 
precipitated with ethanol using standard methods following 
incubation. Samples 6, 7, 13, and 14 were dissolved in 10% 
aqueous piperidine solution (50 ul), heated at 90° C. for 30 
minutes, then freeze-dried. All samples were resuspended in 
50% formamide loading buffer, denatured at 90° C. for 5' 
and analyzed by electrophoresis on a 20% denaturing poly 
acrylamide gel. 
The resulting autoradiograph indicated substantial cleav 
age only in those lanes that contained the appropriate 
complementary 15-mer LuTxp 2'-O-methyl RNA conjugate. 
The cleavage sites covered three to four residues, proximal 
to the anticipated location of the LuTxp complex. These 
cleavages are consistent with a model whereby hybridization 
of the 2'-O-methyl-LuTxp conjugates to their complemen 
tary sequences of DNA increases the local concentration of 
the LuTxp and effects site-specific cleavage. 
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The autoradiograph also contained information regarding 
cleavage mechanism: Certain positions within the cleavage 
site are clearly more reactive to cleavage than others. 
Definitive identification of these more reactive bases awaits 
further experimentation, but are tentatively assigned to posi 
tions containing purine bases. 
The maximal extent of cleavage observed was roughly 
10%, and was obtained using a piperidine treatment of the 
light-exposed samples. The effect of this piperidine treat 
ment is at least a 10-fold increase in cleavage products, 
indicating that initial DNA lesions formed by the photo 
chemical reaction require base assistance to efficiently pro 
duce strand breaks. As the extent of light-induced cleavage 
in non-piperidine-treated lanes is far lower than that 
obtained using laser irradiation, it may be possible to 
observe an increase in the yield of cleavage products by 
using both laser and piperidine treatments. 
A texaphyrin-oligonucleotide conjugate of a derivatized 
RNA such as the 2'-O-methyl RNA analog used herein may 
provide stability against self-cleavage. RNA is hydrolyzed 
by LuTxp, however, the 2'-O-Me RNA lacks a 2'-OH and, 
therefore, is stable to hydrolysis. Therefore, an RNA analog 
oligomer may be more stable than a DNA oligomer for the 
Txp-oligonucleotide conjugate. The synthesis of RNA ana 
log-conjugates is the same as for Txp-DNA conjugates 
discussed previously herein. An RNA-analog conjugate may 
be complementary to an antisense or a sense strand of DNA 




In any of the embodiments concerning matrix-supported 
texaphyrins, a polymeric texaphyrin itself may be employed 
as the texaphyrin species. This Example describes the gen 









a polymer-supported construct, or indeed, in other embodi 
ments in which their polymeric nature would be an advan 
tage, such as those outlined below. Examples 9 and 10 of 
co-pending application, PCT publication WO94/09003, are 
specifically incorporated herein by reference for the pur 
poses of supplementing the present example in terms of 
describing the synthetic methodology underlying the gen 
eration of polymeric species of expanded porphyrins. 
A variety of texaphyrin derivatives are obtainable via 
alkylation of the phenolic precursors prior to cyclization and 
metallation. Some of these derivatives can be treated as 
components in polymer forming reactions. For instance, a 
T2B1-type derivative may be elaborated synthetically to 
provide a diamine substituent that may be polymerized by 
condensation with any of a variety of activated diesters, such 
as that of terephthalic acid as follows. 
Alternatively, a T2B2-type derivative could be elaborated 
to bear two monoamine substituents, that may then be 
polymerized in a similar fashion. 
Addition polymers may also be prepared. Alkylation of 
phenolic precursors with allylic or polyene halides would, 
upon elaboration, produce texaphyrin derivatives having 
alkene or polyene substituents. These compounds would 
serve as components of addition polymerization-type reac 
tions with other alkenes, dienes, or polyenes that may or may 
not contain a texaphyrin as follows. 
The properties of the resulting polymeric materials will 
depend on the identity of the metal cation within the 
macrocycle, substituents on the macrocyclic rim, the identity 
of the copolymer, and the degree and type of polymerization. 
These properties in turn serve to define the application for 
which the polymer may be used. For example, a gadolin 
ium(III) texaphyrin with water solubilizing substituents 
polymerized with a hydrophilic partner to form a copolymer 
with an average molecular weight of 10–20 kiloDalton is 
contemplated to serve as a useful 
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MRI blood pool agent. The size of the drug substance is 30 molecular 
expected to have an effect on its biodistribution and immu 
nogenic properties: for instance, polymeric texaphyrin with 
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weight above 10 kD should be recognized and removed by 
the lymphatic system in normal tissues, while the absence of 
a lymphatic system within tumors should allow the accu 
mulation of the drug in these tissues (U.S. Pat. No. 4,649, 
151). These tumors may then be visualized by MRI, when 
Ln=Gd, or eradicated using PDT, when Ln=Lu. By poly 
merizing a drug substance it is also possible to reduce the 
osmotic load per given dose, thereby reducing its toxicity. 
Alternatively, polymerization of more hydrophobic com 
ponents is contemplated to produce materials suitable for 
molding and shaping. Wires drawn from such a material 
might find application in biological implants, such as cath 
eters, which could be visualized by MRI. Such materials 
could also conceivably find application as semiconducting 
components, due to the organometallic nature of these 
materials, or linear optical devices. 
All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the composition, methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
More specifically, it will be apparent that certain agents 
which are both chemically and physiologically related may 
be substituted for the agents described herein while the same 
or similar results would be achieved. For example, other 
large expanded porphyrins that bind anions are contem 
plated for use in similar embodiments to sapphyrins; and 
expanded porphyrins that contain a Lewis acid center are 
contemplated for use in catalytic hydrolysis, in a similar 
manner to the texaphyrins. All such similar substitutes and 
modifications apparent to those skilled in the art are deemed 
to be within the spirit, scope and concept of the invention as 
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What is claimed is: 
1. A composition comprising a matrix-supported texaphy 
rin 
2. The composition of claim 1 where the matrix is a 
polymericor solid-support matrix. 
3. The composition of claim 1 wherein the texaphyrin is 




4. The composition of claim 3, wherein the metal cation 
is La(III), Nd(III), Sm(III), Sm(II), Gd(III), Tm(III), Lu(III), 
Eu(III), Dy(III), Y(III), In(III), Ce(III), Sc(III), Ca(II), 
Mn(II), Ni(II), Zn(II), CdCII), Hg(II), Mn(III), Co(II), 
Co(III), Ni(III), Fe(II), Fe(III), Cu(II), Ho(III), Pr(III), 
Tb(III), Er(III) or Yb(III). 
5. The composition of claim 3, wherein the metal cation 
is Sm(III), Eu(III), Gd(III) or Dy(III). 
6. The composition of claim 3, wherein the metal cation 
is La(III), Lu(III), or Y(III). 
7. The composition of claim 1 wherein the texaphyrin is 
joined to the matrix by a linker XY, wherein X is 
-(CH) --NH where n is an integer from 0 to 20, OH, 
COH, Cl, Br, I, OH, NCO, NCS, NC, C=CH, CH=CH, 
MgCl, ZnCl, Li, a nucleotide or an oligonucleotide, and Y is 
-(CH), --OH where n is an integer from 0 to 20, NH, 
COH, Cl, Br, I, NCO, NCS, oxirane, C=CH, MgCl, ZnCl, 
Li, a nucleotide or an oligonucleotide. 
8. The composition of claim 1 wherein the texaphyrin is 
joined to the matrix by a linker XY, wherein X is 
-(CH)--OH where n is an integer from 0 to 20, NH2, 
COH, Cl, Br, I, NCO, NCS, oxirane, C=CH, MgCl, ZnCl, 
Li, a nucleotide or an oligonucleotide, and Y is -(CH2) - 
-NH where n is an integer from 0 to 20, OH, COH, Cl, 
Br, I, OH, NCO, NCS, NC, C=CH, CH=CH, MgCl, 
ZnCl, Li, a nucleotide or an oligonucleotide. 
9. The composition of claim 1 wherein the texaphyrin is 
joined to the matrix by an ether, ester, amide, amine, 
carbamate, urea, -CH=CH-, -C=C-, -(CH2), 
where m is an integer from 1 to 20, functionalized alkyl, 
aryl, or oligonucleotide linker. 
10. The composition of claim 1 wherein the matrix is a 
solid-support matrix and the solid-support is silica, silica 
gel, amino-functionalized silica gel, alumina, clay, Zeolite, 
glass, controlled pore glass or montmorillonite. 
11. The composition of claim 1 wherein the matrix is 
silica gel. 
12. The composition of claim 1 wherein the matrix is a 
polymer-support matrix and the polymer is polystyrene, 
polyethylene, polyacrylamide, polypropylene, polyamide, 
Merrifield resin, sepharose, agarose, polystyrene, polydivi 
nylbenzene, cellulose, alginic acid, chitosan, chitin, poly 
styrene-benzhydrylamine resin, an acrylic ester polymer, a 
lactic acid polymer, a texaphyrin multimer or a sapphyrin 
multimer. 
13. The composition of claim 1 wherein the matrix is 
polyurethane, polyvinylchloride, nylon, latex, silicone rub 
ber, a halogenated polyethylene, an organosilicone, a bio 
compatible ceramic, bioglass or sintered hydroxyapatite. 
14. The composition of claim 1 formulated into a column. 
15. The composition of claim 1 formulated into a capillary 
electrophoresis tube. 
16. The composition of claim 1 wherein the matrix 
supported texaphyrin is in the form of a medical device. 
17. The composition of claim 16, wherein the medical 
device is implantable. 
18. The composition of claim 16, where the medical 
device is a catheter, an orthopedic implant, an artificial joint 
or a part thereof. 
19. The composition of claim 1, wherein the texaphyrin 
further comprises a D-sugar unit, an L-sugar unit, an oli 
gosaccharide, an L-amino acid, a D-amino acid, a peptide or 
a polypeptide. 
20. The composition of claim 1, wherein the texaphyrin 
further comprises a nucleobase-containing group. 
21. A method for separating a first molecule from a 














contacting a matrix-supported texaphyrin metal complex 
with said mixture to separate said first molecule. 
22. The method of claim 21, wherein the metal is La(III), 
Nd(III), Sm(III), Sm(II), Gd(III), Tm(III), Lu(III), Eu(III), 
Dy(III), Y(III), InCIII), Ce(III), Sc(III), Ca(II), Mn(II), 
Ni(II), Zn(II), CdCII), Hg(II), Mn(III), Co(II), Co(III), 
Ni(III), Fe(II), Fe(III), Cu(II), Ho(III), Pr(III), Tb(III), 
Er(III) or Yb(III). 
23. The method of claim 21, wherein the matrix-sup 
ported texaphyrin comprises a texaphyrin linked to a poly 
meric or solid-support matrix via an ether, ester, amide, 
amine, carbamate, urea, -CH=CH-, -C=C-, 
-(CH2)- where m is an integer from 1 to 20, function 
alized alkyl, aryl, or oligonucleotide linker. 
24. The method of claim 21, wherein the matrix-sup 
ported texaphyrin comprises a silica, silica gel, amino 
functionalized silica gel, alumina, clay, Zeolite, glass, con 
trolled pore glass, montmorillonite, polystyrene, 
polyethylene, polyacrylamide, polypropylene, polyamide, 
Merrifield resin, sepharose, agarose, polystyrene, polydivi 
nylbenzene, cellulose, alginic acid, chitosan, chitin, poly 
styrene-benzhydrylamine resin, an acrylic ester polymer, a 
lactic acid polymer, a texaphyrin multimer, a Sapphyrin 
multimer, polyurethane, polyvinylchloride, nylon, latex, sili 
cone rubber, a halogenated polyethylene, an organosilicone; 
or a biocompatible ceramic, bioglass or sintered hydroxya 
patite polymeric or solid-support matrix. 
25. The method of claim 21, wherein the matrix-sup 
ported texaphyrin is formulated into an HPLC column, a 
capillary electrophoresis tube or a filter cartridge. 
26. The method of claim 21, wherein said mixture to be 
separated includes a molecule having a chloride, bromide, 
fluoride, pseudohalide, phosphate, phosphonate, phosphate 
ester, arsenate, arsenate ester, carboxylate, nitrate, sulfate, 
sulfonate or sugar moiety within its structure. 
27. The method of claim 21, wherein said mixture to be 
separated includes a molecule having a phosphate, nitrate, 
organophosphorus or nucleotide moiety within its structure. 
28. The method of claim 27, wherein said mixture to be 
separated includes an RNA or DNA molecule. 
29. The method of claim 27, wherein said mixture 
includes a pesticide, an herbicide, a fungicide, or a chemical 
warfare agent. 
30. A method for hydrolysing a phosphate ester, compris 
ing the step of contacting a matrix-supported texaphyrin 
metal complex where the metal cation has catalytic activity 
for ester bond hydrolysis in aqueous solution with the 
phosphate ester to cleave the ester. 
31. The method of claim 30, wherein the metal cation is 
Eu(III) or Dy(III). 
32. The method of claim 30, wherein the phosphate ester 
is a nucleotide, an RNA molecule, a cofactor or a phospho 
lipid. 
33. The method of claim 32, wherein the phosphate ester 
is an RNA molecule. 
34. A method of light-induced cleavage of a polymer of 
deoxyribonucleic acid, the method comprising: 
contacting the polymer with a matrix-supported texaphy 
rin where the texaphyrin is a photosensitive texaphyrin, 
and 
exposing the matrix-supported texaphyrin to light for a 
time sufficient to cleave the polymer. 
35. The method of claim 34 wherein the exposing step is 
carried out in the presence of oxygen. 
36. The method of claim 34 wherein the photosensitive 
texaphyrin is a texaphyrin complexed with a diamagnetic 
metal and the diamagnetic metal is Lu(III), La(III), In(III), 
Zn(II) or CdCII). 
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37. A method for conducting a chemical reaction cata 
lyzed by a lanthanide metal cation comprising the step of 
contacting a matrix-supported texaphyrin complexed to a 
metal cation, where the metal cation is a lanthanide metal 
cation, with a composition comprising the substrates for the 
chemical reaction. 
38. The method of claim 37, wherein the lanthanide metal 
cation is La(III), Sm(III), Gd(III), Y(III), Tb(III), Lu(III), 
Eu(III), Ce(III) or Dy(III). 
39. The method of claim 37, wherein the chemical reac 
tion is ester hydrolysis, amide hydrolysis, phosphate ester 
hydrolysis, acyl transfer, hydrogenation or polymerization. 
40. A method of magnetic resonance imaging of a subject, 
comprising: 
administering a matrix-supported texaphyrin complexed 
to a metal cation, wherein the metal cation is a para 
magnetic metal cation, to the subject; and 
imaging the subject by reference to the matrix-supported 
texaphyrin. 
41. A method of light-induced singlet oxygen production 
comprising subjecting a matrix-supported texaphyrin of 
claim 1 to light in the presence of oxygen. 
64 
42. A method of photodynamic tumor therapy comprising: 
contacting a matrix-supported texaphyrin with a compo 
sition suspected of having tumor cells; and 
photoirradiating the matrix-supported texaphyrin in con 
tact with the composition. 
43. A method for deactivating a retrovirus or an enveloped 
virus comprising 
contacting a matrix-supported texaphyrin with a compo 
sition suspected of having a retrovirus or enveloped 
virus; and 
photoirradiating the matrix-supported texaphyrin in con 
tact with the composition. 
44. The composition of claim 2 where the matrix is a 
polymeric matrix and the polymeric matrix is a texaphyrin 
20 multimer. 
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